# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K211748

B Applicant Selux Diagnostics, Inc

C Proprietary and Established Names Selux AST System; Model AST Gen 1.0

# D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LON</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.1645 - FullyAutomated Short-TermIncubation CycleAntimicrobialSusceptibility System</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr><tr><td rowspan=1 colspan=1>LTT</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.1640 -Antimicrobialsusceptibility test powder</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr><tr><td rowspan=1 colspan=1>LTW</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.1640 -Antimicrobialsusceptibility test powder</td><td rowspan=1 colspan=1>MI - Microbiology</td></tr></table>

# II Submission/Device Overview:

# A Purpose for Submission:

To obtain substantial equivalence determination for Gram-negative organisms tested with the Selux AST System to determine the minimum inhibitory concentration of specific antimicrobials with specific Gram-negative organisms.

# B Measurand:

# Antimicrobial

Amikacin   
Amoxicillin-Clavulanate Ampicillin   
Ampicillin-Sulbactam

Reportable Range ${ \le } 0 . 1 2$ to $\geq 2 5 6 ~ \mu \mathrm { g / m L }$ $\le 0 . 5$ to $\geq 1 2 8 \ \mu \mathrm { g / m L }$ ${ \le } 0 . 2 5$ to $\geq 1 2 8 \ { \mu \mathrm { g / m L } }$ $\le 0 . 5$ to $\geq 1 2 8 \ { \mu } { \mathrm { g / m L } }$

# Antimicrobial

Aztreonam   
Cefazolin   
Cefepime   
Cefoxitin   
Ceftazidime   
Ceftazidime-Avibactam   
Ceftriaxone   
Ciprofloxacin   
Eravacycline   
Ertapenem   
Gentamicin   
Imipenem-Relebactam   
Levofloxacin   
Meropenem   
Meropenem-Vaborbactam   
Minocycline   
Piperacillin-Tazobactam   
Tobramycin   
Trimethoprim-Sulfamethoxazole

Reportable Range ${ \le } 0 . 0 3$ to $\geq 1 2 8 \ { \mu \mathrm { g / m L } }$ ${ \le } 0 . 1 2$ to $\geq 1 2 8 \ { \mu \mathrm { g / m L } }$ ${ \le } 0 . 2 5$ to $\geq 1 2 8 \ { \mu \mathrm { g / m L } }$ $\leq 1$ to $\geq 1 2 8 \ { \mu \mathrm { g / m L } }$ ${ \le } 0 . 2 5$ to ${ \geq } 6 4 ~ \mu \mathrm { g / m L }$ ${ \le } 0 . 1 2$ to ${ \geq } 6 4 ~ \mu \mathrm { g / m L }$ ${ \le } 0 . 2 5$ to $2 3 2 ~ \mu \mathrm { g / m L }$ ${ \le } 0 . 0 3$ to $2 1 6 ~ \mu \mathrm { g / m L }$ ${ \le } 0 . 0 1 6$ to ${ \geq } 4 ~ \mu \mathrm { g / m L }$ ${ \le } 0 . 0 3$ to $2 1 6 ~ \mu \mathrm { g / m L }$ ${ \leq } 0 . 0 6$ to ${ \geq } 6 4 ~ \mu \mathrm { g / m L }$ ${ \le } 0 . 0 3$ to $\geq 1 2 8 \ { \mu \mathrm { g / m L } }$ ${ \leq } 0 . 0 6$ to $2 3 2 ~ \mu \mathrm { g / m L }$ ${ \le } 0 . 1 2$ to ${ \geq } 6 4 ~ \mu \mathrm { g / m L }$ ${ \leq } 0 . 0 6$ to ${ \geq } 6 4 ~ \mu \mathrm { g / m L }$ ${ \le } 0 . 2 5$ to ${ \geq } 6 4 ~ \mu \mathrm { g / m L }$ ${ \le } 0 . 2 5$ to $\geq 5 1 2 \mu \mathrm { g / m L }$ ${ \le } 0 . 1 2$ to $\geq 1 2 8 \ { \mu \mathrm { g / m L } }$ ${ \le } 0 . 1 2$ to $2 3 2 ~ \mu \mathrm { g / m L }$

# C Type of Test:

Quantitative antimicrobial susceptibility test (AST) system that utilizes colorimetric, oxidationreduction and growth-based strategies to determine the minimum inhibitory concentration (MIC) of specific antimicrobial-organism combinations.

# III Intended Use/Indications for Use:

# A Intended Use(s):

The Selux AST System is intended to be used for the automated quantitative or qualitative susceptibility testing for most clinically significant aerobic microorganisms. The Selux AST System does not provide organism identification.

# B Indication(s) for Use:

The Selux Gram-Negative Panel is intended for use with the Selux AST System as an in vitro test to determine the susceptibility of isolated colonies of specific gram-negative bacilli to specific antimicrobial agents when used as instructed.

The Selux Gram-Negative Panel is a quantitative test for the following antimicrobial agents with the specific organisms identified below:

• Amikacin: Pseudomonas aeruginosa Amoxicillin-Clavulanate: Escherichia coli, Klebsiella species (including K. oxytoca, K. pneumoniae), Proteus mirabilis Ampicillin: Escherichia coli, Proteus mirabilis Ampicillin-Sulbactam: Acinetobacter baumannii complex, Escherichia coli, Klebsiella species (including K. oxytoca, K. pneumoniae), Proteus mirabilis, Proteus vulgaris   
• Aztreonam: Escherichia coli Cefazolin: Escherichia coli, Klebsiella pneumoniae   
Cefepime: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae,   
Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens   
Cefoxitin: Escherichia coli, Klebsiella species (including K. oxytoca, K. pneumoniae), Morganella morganii   
Ceftazidime: Citrobacter species (including C. freundii complex, C. koseri), Enterobacter cloacae complex, Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae), Proteus mirabilis, Proteus vulgaris, Serratia marcescens   
Ceftazidime-Avibactam: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens   
Ceftriaxone: Citrobacter freundii complex, Citrobacter koseri, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis   
Ciprofloxacin: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa Eravacycline: Citrobacter freundii complex, Enterobacter cloacae complex, Escherichia coli, Klebsiella oxytoca   
Ertapenem: Citrobacter freundii complex, Citrobacter koseri, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens   
Gentamicin: Citrobacter species (including C. freundii complex, C. koseri), Enterobacter cloacae complex, Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae), Proteus species (including $P .$ . mirabilis, P. vulgaris), Pseudomonas aeruginosa, Serratia marcescens   
Imipenem-Relebactam: Citrobacter freundii complex, Citrobacter koseri, Escherichia coli, Klebsiella oxytoca, Pseudomonas aeruginosa   
Levofloxacin: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens   
Meropenem: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens Meropenem-Vaborbactam: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Serratia marcescens   
Minocycline: Escherichia coli, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae)   
Piperacillin-Tazobactam: Citrobacter koseri, Escherichia coli, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris   
Tobramycin: Pseudomonas aeruginosa   
Trimethoprim-Sulfamethoxazole: Enterobacter cloacae complex, Klebsiella species (including K. aerogenes, K. oxytoca, K. pneumoniae)

# C Special Conditions for Use Statement(s):

• Rx - For Prescription Use Only

The following limitations were added to the device labeling based on performance demonstrated in the current submission:

The ability of the Selux AST system to detect resistance in the following   
antimicrobial/organism combinations is unknown because an insufficient number of resistan   
isolates were available at the time of comparative testing: Ampicillin-Sulbactam: Proteus vulgaris Cefepime: Klebsiella aerogenes, Morganella morganii, Proteus vulgaris, Serratia marcescens Cefoxitin: Klebsiella oxytoca Ceftazidime-avibactam: Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens Ciprofloxacin: Citrobacter koseri, Proteus vulgaris Eravacycline: Escherichia coli, Klebsiella oxytoca Ertapenem: Citrobacter koseri, Klebsiella oxytoca, Morganella morganii, Proteus mirabilis, Proteus vulgaris Gentamicin: Klebsiella aerogenes, Morganella morganii, Proteus vulgaris, Serratia marcescens Imipenem-Relebactam: Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca Levofloxacin: Citrobacter koseri Meropenem: Citrobacter koseri, Klebsiella oxytoca, Morganella morganii, Proteus vulgaris Meropenem-vaborbactam: Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens Minocycline: Klebsiella oxytoca Piperacillin-tazobactam: Citrobacter koseri, Proteus mirabilis, Proteus vulgaris

• Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Amikacin: Acinetobacter baumannii   
Ampicillin: Proteus mirabilis when the Selux MIC is $2 \mu \mathrm { g / m L }$ due to one very major error Ampicillin-Sulbactam: Proteus vulgaris when the Selux MIC is $3 2 ~ \mu \mathrm { g / m L }$ due to 3 major errors Aztreonam: Pseudomonas aeruginosa Cefazolin: Proteus mirabilis Cefepime: Klebsiella aerogenes when the Selux MIC is ${ \geq } 6 4 ~ \mu \mathrm { g / m L }$ due to 2 major errors, Pseudomonas aeruginosa Cefoxitin: Proteus mirabilis, Proteus vulgaris Ceftazidime: Acinetobacter baumannii, Pseudomonas aeruginosa Ceftriaxone: Enterobacter cloacae, Serratia marcescens Ciprofloxacin: Serratia marcescens Eravacycline: Klebsiella pneumoniae Ertapenem: Citrobacter freundii complex when the Selux MIC is 2, 4, or $8 ~ \mu \mathrm { g / m L }$ due to 3 major errors, Enterobacter cloacae, Klebsiella aerogenes Gentamicin: Pseudomonas aeruginosa when the Selux MIC is $\leq 0 . 0 6 ~ \mu \mathrm { g / m L }$   
Imipenem: Acinetobacter baumannii   
Imipenem-Relebactam: Klebsiella oxytoca when the Selux MIC is $4 ~ \mu \mathrm { g / m L }$ due to one   
major error, Klebsiella aerogenes, Klebsiella pneumoniae   
Levofloxacin: Citrobacter freundii complex when the Selux MIC is $2 ~ { \mu \mathrm { g / m L } }$ due to 2   
major errors, Klebsiella aerogenes when the Selux MIC is $2 ~ { \mu \mathrm { g / m L } }$ due to one major   
error, Pseudomonas aeruginosa   
Meropenem: Acinetobacter baumannii, Citrobacter freundii complex when the Selux   
MIC is 16 or $3 2 ~ \mu \mathrm { g / m L }$ due to 3 major errors, Serratia marcescens when the Selux MIC   
is 16 or $3 2 ~ \mu \mathrm { g / m L }$ due to 4 major errors   
Meropenem-Vaborbactam: Proteus mirabilis, Proteus vulgaris   
Minocycline: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae when   
the Selux MIC is $4 ~ \mu \mathrm { g / m L }$ due to 2 very major errors   
Piperacillin-Tazobactam: Acinetobacter baumannii, Citrobacter freundii, Enterobacter   
cloacae, Klebsiella aerogenes, Pseudomonas aeruginosa, Serratia marcescens   
Trimethoprim-Sulfamethoxazole: Citrobacter freundii, Escherichia coli

# D Special Instrument Requirements:

Selux AST System, Software version 1, subversion 8.168

# IV Device/System Characteristics:

# A Device Description:

The Selux AST System is an antimicrobial susceptibility test (AST) system that consists of a Sample Prep Station, an Inoculator, an Analyzer, a computer workstation, and the reagents and consumables required to perform AST testing. The system is operated via software that guides users through the manual sample preparation process and operates the automated Inoculator and Analyzer. The software includes an algorithm that enables the system to determine the susceptibility of an organism to the variety of antimicrobials provided in the Selux AST panels. The system is designed so that only Gram stain information is required to initiate testing to select the gram-negative or gram-positive antimicrobial panel. While complete system testing can be performed without species-level identification, this information is required for the system to report susceptibility results. Species identification information can be either manually input to the Selux system or automatically downloaded from the laboratory information system (LIS) at any time, once the sample ID is entered into the LIS.

The Selux AST Systems provides the following consumables: AST panels, panel lids, tubes and caps for sample prep, troughs for inoculator, McFarland Standards for densitometer performance checks, inoculator pipette tips, inoculator waste bins, inoculator growth media, inoculator cleaning solution, analyzer reagent packs, analyzer liquid waste disinfectant tablets, analyzer absorbent waste pads, and an analyzer solid waste bag.

The Selux AST System is divided into three primary AST steps performed at three different stations: workbench (for sample preparation), panel inoculator (for inoculation), and AST analyzer (for antimicrobial susceptibility testing), as described in detail in the Device Description section of K211759.

The Selux AST System with the Gram-Negative Panel can determine the MIC of various antimicrobials when tested against specific organisms Table 1.

Table 1. Reportable MIC Ranges and Organism-Specific Breakpoints for Antimicrobials included in the Selux AST System, Gram-Negative Panel   

<table><tr><td rowspan=2 colspan=1>Antimicrobial</td><td rowspan=2 colspan=1>Organism Group</td><td rowspan=2 colspan=1>Selux AST SystemReportable Range(μg/mL)</td><td rowspan=1 colspan=3>FDA-Recognized/Approved Breakpoints (μg/mL)</td></tr><tr><td rowspan=1 colspan=1>S</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>R</td></tr><tr><td rowspan=1 colspan=1>Amikacin</td><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>≤0.12 to ≥256</td><td rowspan=1 colspan=1>≤16</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>≥64</td></tr><tr><td rowspan=1 colspan=1>Amoxicillin-Clavulanate</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.5 to ≥128</td><td rowspan=1 colspan=1>≤8</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>≥32</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.25 to ≥128</td><td rowspan=1 colspan=1>≤8</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>≥32</td></tr><tr><td rowspan=1 colspan=1>Ampicillin-Sulbactam</td><td rowspan=1 colspan=1>Acinetobacter baumannii complexEnterobacterales</td><td rowspan=1 colspan=1>≤0.5 to ≥128</td><td rowspan=1 colspan=1>≤8</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>≥32</td></tr><tr><td rowspan=1 colspan=1>Aztreonam</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.03 to ≥128</td><td rowspan=1 colspan=1>≤4</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>≥16</td></tr><tr><td rowspan=1 colspan=1>Cefazolin</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.12 to ≥128</td><td rowspan=1 colspan=1>≤1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>≥4</td></tr><tr><td rowspan=1 colspan=1>Cefepime</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.25 to ≥128</td><td rowspan=1 colspan=1>≤2</td><td rowspan=1 colspan=1>4-8</td><td rowspan=1 colspan=1>≥16</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤1 to ≥128</td><td rowspan=1 colspan=1>≤4</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>≥16</td></tr><tr><td rowspan=1 colspan=1>Ceftazidime</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.25 to ≥64</td><td rowspan=1 colspan=1>≤4</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>≥16</td></tr><tr><td rowspan=1 colspan=1>Ceftazidime-Avibactam</td><td rowspan=1 colspan=1>EnterobacteralesPseudomonas aeruginosa</td><td rowspan=1 colspan=1>≤0.12 to ≥64</td><td rowspan=1 colspan=1>≤8</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>≥16</td></tr><tr><td rowspan=1 colspan=1>Ceftriaxone</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.25 to ≥32</td><td rowspan=1 colspan=1>≤1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>≥4</td></tr><tr><td rowspan=2 colspan=1>Ciprofloxacin</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=2 colspan=1>≤0.03 to ≥16</td><td rowspan=1 colspan=1>≤0.25</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>≥1</td></tr><tr><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>≤0.5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>≥2</td></tr><tr><td rowspan=1 colspan=1>Eravacycline</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.016 to ≥4</td><td rowspan=1 colspan=1>≤0.5</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>Ertapenem</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.03 to ≥16</td><td rowspan=1 colspan=1>≤0.5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>≥2</td></tr><tr><td rowspan=1 colspan=1>Gentamicin</td><td rowspan=1 colspan=1>EnterobacteralesPseudomonas aeruginosa</td><td rowspan=1 colspan=1>≤0.06 to ≥64</td><td rowspan=1 colspan=1>≤4</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>≥16</td></tr><tr><td rowspan=2 colspan=1>Imipenem-Relebactam</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=2 colspan=1>≤0.03 to ≥128</td><td rowspan=1 colspan=1>≤1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>≥4</td></tr><tr><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>≤2</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>≥8</td></tr><tr><td rowspan=1 colspan=1>Levofloxacin</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.06 to ≥32</td><td rowspan=1 colspan=1>≤0.5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>≥2</td></tr><tr><td rowspan=2 colspan=1>Meropenem</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=2 colspan=1>≤0.12 to ≥64</td><td rowspan=1 colspan=1>≤1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>≥4</td></tr><tr><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>≤2</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>≥8</td></tr><tr><td rowspan=1 colspan=1>Meropenem-Vaborbactam</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.06 to ≥64</td><td rowspan=1 colspan=1>≤4</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>≥16</td></tr><tr><td rowspan=1 colspan=1>Minocycline</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.25 to ≥64</td><td rowspan=1 colspan=1>≤4</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>≥16</td></tr><tr><td rowspan=1 colspan=1>Piperacillin-Tazobactam</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.25 to ≥512</td><td rowspan=1 colspan=1>≤16</td><td rowspan=1 colspan=1>32-64</td><td rowspan=1 colspan=1>≥128</td></tr><tr><td rowspan=1 colspan=1>Tobramycin</td><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>≤0.12 to ≥128</td><td rowspan=1 colspan=1>≤4</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>≥16</td></tr><tr><td rowspan=1 colspan=1>Trimethoprim-Sulfamethoxazole</td><td rowspan=1 colspan=1>Enterobacterales</td><td rowspan=1 colspan=1>≤0.12 to ≥32</td><td rowspan=1 colspan=1>≤2</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>≥4</td></tr></table>

S, Susceptible; I, Intermediate; R, Resistant; -, no breakpoint (interpretive criterion) recognized

# B Principle of Operation:

The Selux AST test requires that the Gram type of the organism be known prior to testing as the information is necessary to select the proper AST panel to use (i.e., gram-positive or gramnegative). The organism identification (ID) is not needed for Selux AST processing to be performed; however, the organism ID is necessary for a final result to be reported.

The Selux AST System performs antimicrobial susceptibility testing similar to the gold-standard broth microdilution method. To get an accurate reading of microbial growth, the sufficient growth assay monitors growth in dedicated AST panel wells that contain organisms and cationadjusted Mueller-Hinton Broth but no antimicrobials or probes. Sufficient growth assay wells are monitored by fluorescence to those wells which the standard metabolism-based viability assay pair resazurin/methylene blue have been added and/or by optical absorbance. Two probe-based assays commence across all wells in the panel after the threshold in the sufficient growth well has been met. The “viability assay” uses a fluorescent metabolic probe as an indicator of cellular activity and the “surface area assay” uses a fluorescent cationic probe that binds microorganism surfaces as a proxy for cellular surface area. The viability and surface area assays are performed in each AST panel well, providing two complementary datasets for each well. These data are input to an MIC-determining algorithm that provides results when organism IDs are available.

Refer to the K211759 Decision Summary for additional information on the Selux AST System.

# V Substantial Equivalence Information:

A Predicate Device Name(s): BD Phoenix Automated Microbiology System - GN Ceftaroline $( 0 . 0 1 5 6  – 4 \mu \mathrm { g / m L } )$   
B Predicate 510(k) Number(s): K190905   
C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp;PredicateDevice(s):</td><td colspan="1" rowspan="1">Device:K211748</td><td colspan="1" rowspan="1">Predicate:K190905</td></tr><tr><td colspan="1" rowspan="1">Device TradeName</td><td colspan="1" rowspan="1">Selux AST System</td><td colspan="1" rowspan="1">BD Phoenix AutomatedMicrobiology System - GNCeftaroline (0.0156-4 μg/mL)</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Similarities</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications ForUse</td><td colspan="1" rowspan="1">The Selux AST System is intended to be used for theautomated quantitative or qualitative susceptibilitytesting for most clinically significant aerobicmicroorganisms. The Selux AST System does notprovide organism identification.The Selux Gram-Negative Panel is intended for usewith the Selux AST System as an in vitro test todetermine the susceptibility of isolated colonies ofspecific gram-negative bacilli to specific antimicrobialagents when used as instructed.*</td><td colspan="1" rowspan="1">The BD Phoenix Automated MicrobiologySystem is intended for in vitro quantitativedetermination of antimicrobialsusceptibility by minimal inhibitoryconcentration (MIC) of most Gram-negative aerobic and facultative anaerobicbacteria isolates from pure culture forEnterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culturebelonging to the genera Staphylococcus,Enterococcus and Streptococcus.</td></tr><tr><td colspan="1" rowspan="1">Source ofMicroorganisms</td><td colspan="1" rowspan="1">Bacterial colonies isolated from culture</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Automated growth-based detection using metabolicindicators to detect organism growth</td><td colspan="1" rowspan="1">Automated growth based enhanced by useof a redox indicator (colorimetric oxidation-reduction) to detect organism growth</td></tr><tr><td colspan="1" rowspan="1">Panel Type</td><td colspan="1" rowspan="1">Gram-negative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Read Method</td><td colspan="1" rowspan="1">Automated</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Inoculation Method</td><td colspan="1" rowspan="1">Automated</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Result Reported</td><td colspan="1" rowspan="1">Report results as minimum inhibitory concentration(MIC) and categorical interpretation (S, I, R, NS)</td><td colspan="1" rowspan="1">Report results as minimum inhibitoryconcentration (MIC) and categoricalinterpretation (S, I, R)</td></tr><tr><td colspan="1" rowspan="1">Indicated Species</td><td colspan="1" rowspan="1">Acinetobacter baumannii complex, specificEnterobacterales species, and Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">Specific Enterobacterales species</td></tr><tr><td colspan="3" rowspan="1">General Device Characteristic Differences</td></tr><tr><td colspan="1" rowspan="1">AntimicrobialAgent andReporting Range</td><td colspan="1" rowspan="1">Amikacin ≤0.12 to ≥256 µg/mLAmoxicillin-Clavulanate ≤0.5 to ≥128 μg/mLAmpicillin ≤0.25 to ≥128 μg/mLAmpicillin-Sulbactam ≤0.5 to ≥128 μg/mLAztreonam ≤0.03 to ≥128 μg/mLCefazolin ≤0.12 to ≥128 μg/mLCefepime ≤0.25 to ≥128 μg/mLCefoxitin ≤1 to ≥128 μg/mLCeftazidime ≤0.25 to ≥64 μg/mLCeftazidime-Avibactam ≤0.12 to ≥64 µg/mLCeftriaxone ≤0.25 to ≥32 µg/mLCiprofloxacin ≤0.03 to ≥16 μg/mLEravacycline ≤0.016 to ≥4 µg/mLErtapenem ≤0.03 to ≥16 µg/mLGentamicin ≤0.06 to ≥64 μg/mLImipenem ≤0.016 to ≥64 μg/mLImipenem-Relebactam ≤0.03 to ≥128 μg/mLLevofloxacin ≤0.06 to ≥32 μg/mLMeropenem ≤0.12 to ≥64 μg/mLMeropenem-Vaborbactam ≤0.06 to ≥64 µg/mLMinocycline ≤0.25 to ≥64 µg/mLPiperacillin-Tazobactam ≤0.25 to ≥512 μg/mLTobramycin ≤0.12 to ≥128 μg/mLTrimethoprim-Sulfamethoxazole ≤0.12 to ≥32 µg/mL</td><td colspan="1" rowspan="1">Ceftaroline 0.0156-4 µg/mL</td></tr><tr><td colspan="1" rowspan="1">IVD Functions</td><td colspan="1" rowspan="1">AST</td><td colspan="1" rowspan="1">ID and AST</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">Selux AST System</td><td colspan="1" rowspan="1">BD Phoenix Automated MicrobiologySystem</td></tr></table>

\* The Selux Gram-Negative Panel is a quantitative test for the antimicrobial agents with the specific organisms listed in section III.B (Indications for Use Statement).

# VI Standards/Guidance Documents Referenced:

FDA Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA (Issued August 28, 2009)   
CLSI M100-M30, “Performance Standards for Antimicrobial Susceptibility Testing”; Thirtieth Edition (January 2020)

VII Performance Characteristics (if/when applicable):

A Analytical Performance:

1. Precision/Reproducibility:

Reproducibility testing for the Selux AST System with the Gram-Negative Panel was conducted at 3 testing sites (2 external and 1 internal site). Panel members generally consisted of species indicated for use with each respective antimicrobial. To accommodate the numerous antimicrobial/organism combinations being tested concurrently, up to three non-indicated species, within an indicated genus or family, were considered acceptable for testing. Reproducibility was determined from the total number (and percent) of results that fell within one dilution $+ / -$ one doubling dilution) of the modal MIC result for quantitative assays divided by the total number of results. Reproducibility was evaluated between sites (inter-site) and within sites (intra-site). Both best-case (assumes that off-scale results are within one dilution of the mode) and worst-case (assumes that off-scale results are more than one dilution of the mode) performance was determined for each antimicrobial, as outlined in the AST Special Controls Guidance.

In the initial study, inter-site reproducibility was evaluated at three sites by testing at least 25 isolates with on-scale MIC values for each antimicrobial, for a minimum of 75 results per antimicrobial (25 isolates $\textbf { X } 3$ sites $= 7 5$ results/antimicrobial). In general, best-case inter-site reproducibility was acceptable $( \geq 9 5 \% )$ and a sufficient number of results obtained $( \geq 7 5$ results). However, antimicrobials with inter-site worst-case reproducibility of $- 8 9 \%$ or an insufficient number of results generated (i.e., ${ < } 7 5$ ) in the initial study were further evaluated in a supplemental study in which testing was performed with three instruments. Data from both studies are collated and summarized in Table 2. Performance is summarized for each antimicrobial tested with all organisms as well as indicated organisms only. Inter-site reproducibility was determined to be acceptable.

Table 2. Inter-site Reproducibility of Selux AST System (Gram Negative Panel)   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">All organisms (combined)</td><td colspan="2" rowspan="1">Indicated organisms only</td></tr><tr><td colspan="1" rowspan="1">Antimicrobial</td><td colspan="1" rowspan="1">Best-case (%)</td><td colspan="1" rowspan="1">Worst-case (%)</td><td colspan="1" rowspan="1">Best-case (%)</td><td colspan="1" rowspan="1">Worst-case (%)</td></tr><tr><td colspan="1" rowspan="1">Amikacin</td><td colspan="1" rowspan="1">98/104 (94.2%)</td><td colspan="1" rowspan="1">98/104 (94.2%)</td><td colspan="1" rowspan="1">92/98 (93.9%)</td><td colspan="1" rowspan="1">92/98 (93.9%)</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin-Clavulanate</td><td colspan="1" rowspan="1">77/78 (98.7%)</td><td colspan="1" rowspan="1">76/78 (97.4%)</td><td colspan="1" rowspan="1">71/72 (98.6%)</td><td colspan="1" rowspan="1">70/72 (97.2%)</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">72/75 (96%)</td><td colspan="1" rowspan="1">72/75 (96%)</td><td colspan="1" rowspan="1">68/69 (98.6%)</td><td colspan="1" rowspan="1">68/69 (98.6%)</td></tr><tr><td colspan="1" rowspan="1">Ampicillin-Sulbactam</td><td colspan="1" rowspan="1">74/75 (98.7%)</td><td colspan="1" rowspan="1">74/75 (98.7%)</td><td colspan="1" rowspan="1">69/69 (100%)</td><td colspan="1" rowspan="1">69/69 (100%)</td></tr><tr><td colspan="1" rowspan="1">Aztreonam</td><td colspan="1" rowspan="1">77/78 (98.7%)</td><td colspan="1" rowspan="1">75/78 (96.2%)</td><td colspan="1" rowspan="1">77/78 (98.7%)</td><td colspan="1" rowspan="1">75/78 (96.2%)</td></tr><tr><td colspan="1" rowspan="1">Cefazolina</td><td colspan="1" rowspan="1">77/81 (95.1%)</td><td colspan="1" rowspan="1">76/81 (93.8%)</td><td colspan="1" rowspan="1">68/72 (94.4%)</td><td colspan="1" rowspan="1">67/72 (93.1%)</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">77/78 (98.7%)</td><td colspan="1" rowspan="1">76/78 (97.4%)</td><td colspan="1" rowspan="1">77/78 (98.7%)</td><td colspan="1" rowspan="1">76/78 (97.4%)</td></tr><tr><td colspan="1" rowspan="1">Cefoxitin</td><td colspan="1" rowspan="1">73/75 (97.3%)</td><td colspan="1" rowspan="1">72/75 (96.0%)</td><td colspan="1" rowspan="1">70/72 (97.2%)</td><td colspan="1" rowspan="1">69/72 (95.8%)</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">77/81 (95.1%)</td><td colspan="1" rowspan="1">76/81 (93.8%)</td><td colspan="1" rowspan="1">77/81 (95.1%)</td><td colspan="1" rowspan="1">76/81 (93.8%)</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-Avibactam</td><td colspan="1" rowspan="1">140/144 (97.2%)</td><td colspan="1" rowspan="1">139/144 (96.5%)</td><td colspan="1" rowspan="1">140/144 (97.2%)</td><td colspan="1" rowspan="1">139/144 (96.5%)</td></tr><tr><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">140/141 (99.3%)</td><td colspan="1" rowspan="1">140/141 (99.3%)</td><td colspan="1" rowspan="1">140/141 (99.3%)</td><td colspan="1" rowspan="1">140/141 (99.3%)</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacina</td><td colspan="1" rowspan="1">74/75 (98.7%)</td><td colspan="1" rowspan="1">71/75 (94.7%)</td><td colspan="1" rowspan="1">74/75 (98.7%)</td><td colspan="1" rowspan="1">71/75 (94.7%)</td></tr><tr><td colspan="1" rowspan="1">Eravacycline</td><td colspan="1" rowspan="1">78/78 (100%)</td><td colspan="1" rowspan="1">78/78 (100%)</td><td colspan="1" rowspan="1">78/78 (100%)</td><td colspan="1" rowspan="1">78/78 (100%)</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">143/145 (98.6%)</td><td colspan="1" rowspan="1">143/145 (98.6%)</td><td colspan="1" rowspan="1">143/145 (98.6%)</td><td colspan="1" rowspan="1">143/145 (98.6%)</td></tr><tr><td colspan="1" rowspan="1">Gentamicina</td><td colspan="1" rowspan="1">77/80 (96.3%)</td><td colspan="1" rowspan="1">77/80 (96.3%)</td><td colspan="1" rowspan="1">77/80 (96.3%)</td><td colspan="1" rowspan="1">77/80 (96.3%)</td></tr><tr><td colspan="1" rowspan="1">Imipenem</td><td colspan="1" rowspan="1">145/149 (97.3%)</td><td colspan="1" rowspan="1">140/149 (94.0%)</td><td colspan="1" rowspan="1">145/149 (97.3%)</td><td colspan="1" rowspan="1">140/149 (94.0%)</td></tr><tr><td colspan="1" rowspan="1">Imipenem-Relebactam</td><td colspan="1" rowspan="1">71/75 (94.7%)</td><td colspan="1" rowspan="1">71/75 (94.7%)</td><td colspan="1" rowspan="1">71/75 (94.7%)</td><td colspan="1" rowspan="1">71/75 (94.7%)</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">76/78 (97.4%)</td><td colspan="1" rowspan="1">76/78 (97.4%)</td><td colspan="1" rowspan="1">73/75 (97.3%)</td><td colspan="1" rowspan="1">73/75 (97.3%)</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">75/78 (96.2%)</td><td colspan="1" rowspan="1">73/78 (93.6%)</td><td colspan="1" rowspan="1">70/72 (97.2%)</td><td colspan="1" rowspan="1">68/72 (94.4%)</td></tr><tr><td colspan="1" rowspan="1">Meropenem-Vaborbactam</td><td colspan="1" rowspan="1">142/145 (97.9%)</td><td colspan="1" rowspan="1">132/145 (91.0%)</td><td colspan="1" rowspan="1">142/145 (97.9%)</td><td colspan="1" rowspan="1">132/145 (91.0%)</td></tr><tr><td colspan="1" rowspan="1">Minocyclinea</td><td colspan="1" rowspan="1">73/75 (97.3%)</td><td colspan="1" rowspan="1">73/75 (97.3%)</td><td colspan="1" rowspan="1">64/66 (97.3%)</td><td colspan="1" rowspan="1">64/66 (97.3%)</td></tr><tr><td colspan="1" rowspan="1">Piperacillin-Tazobactama</td><td colspan="1" rowspan="1">72/75 (96.0%)</td><td colspan="1" rowspan="1">69/75 (92.0%)</td><td colspan="1" rowspan="1">63/66 (95.5%)</td><td colspan="1" rowspan="1">60/66 (90.9%)</td></tr><tr><td colspan="1" rowspan="1">Tobramycin</td><td colspan="1" rowspan="1">74/78 (94.9%)</td><td colspan="1" rowspan="1">73/78 (93.6%)</td><td colspan="1" rowspan="1">74/78 (94.9%)</td><td colspan="1" rowspan="1">73/78 (93.6%)</td></tr><tr><td colspan="1" rowspan="1">Trimethoprim-Sulfamethoxazole</td><td colspan="1" rowspan="1">143/148 (96.6%)</td><td colspan="1" rowspan="1">142/148 (95.9%)</td><td colspan="1" rowspan="1">143/148 (96.6%)</td><td colspan="1" rowspan="1">142/148 (95.9%)</td></tr></table>

a In instances where the original study had lower than the required number, supplemental testing was conducted and data collated with original data.

Intra-site reproducibility was evaluated by testing a minimum of five isolates in triplicate on three days at one internal site for each antimicrobial to generate a minimum of 45 results per antimicrobial (5 isolates x 3 replicates $\mathrm { ~ x ~ 3 ~ d a y s = 4 5 }$ results/antimicrobial). In general, bestcase intra-site reproducibility was acceptable $( \geq 9 5 \% )$ and a sufficient number of results obtained $( \geq 4 5$ results). However, antimicrobials with worst-case reproducibility $- 8 9 \%$ or an insufficient number of results generated (i.e., ${ < } 4 5$ ) in the initial study were further evaluated in a supplemental study. Data from both studies are collated and summarized in Table 3. Performance is summarized for each antimicrobial tested with all organisms as well as indicated organisms only. Intra-site reproducibility was determined to be acceptable.

Table 3. Intra-site Reproducibility of Selux AST System (Gram Negative Panel)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>All organisms (combined)</td><td rowspan=1 colspan=2>Indicated organisms only</td></tr><tr><td rowspan=1 colspan=1>Antimicrobial</td><td rowspan=1 colspan=1>Best-case (%)</td><td rowspan=1 colspan=1>Worst-case (%)</td><td rowspan=1 colspan=1>Best-case (%)</td><td rowspan=1 colspan=1>Worst-case (%)</td></tr><tr><td rowspan=1 colspan=1>Amoxicillin-Clavulanate</td><td rowspan=1 colspan=1>63/63 (100%)</td><td rowspan=1 colspan=1>63/63 (100%)</td><td rowspan=1 colspan=1>63/63 (100%)</td><td rowspan=1 colspan=1>63/63 (100%)</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>45/45 (100%)</td><td rowspan=1 colspan=1>45/45 (100%)</td><td rowspan=1 colspan=1>45/45 (100%)</td><td rowspan=1 colspan=1>45/45 (100%)</td></tr><tr><td rowspan=1 colspan=1>Ampicillin-Sulbactam</td><td rowspan=1 colspan=1>72/72 (100%)</td><td rowspan=1 colspan=1>72/72 (100%)</td><td rowspan=1 colspan=1>72/72 (100%)</td><td rowspan=1 colspan=1>72/72 (100%)</td></tr><tr><td rowspan=1 colspan=1>Aztreonam</td><td rowspan=1 colspan=1>71/74 (95.9%)</td><td rowspan=1 colspan=1>68/74 (91.9%)</td><td rowspan=1 colspan=1>71/74 (95.9%)</td><td rowspan=1 colspan=1>68/74 (91.9%)</td></tr><tr><td rowspan=1 colspan=1>Cefazolin</td><td rowspan=1 colspan=1>61/63 (96.8%)</td><td rowspan=1 colspan=1>61/63 (96.8%)</td><td rowspan=1 colspan=1>61/63 (96.8%)</td><td rowspan=1 colspan=1>61/63 (96.8%)</td></tr><tr><td rowspan=1 colspan=1>Cefepime</td><td rowspan=1 colspan=1>45/47 (95.7%)</td><td rowspan=1 colspan=1>45/47 (95.7%)</td><td rowspan=1 colspan=1>45/47 (95.7%)</td><td rowspan=1 colspan=1>45/47 (95.7%)</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>54/54 (100%)</td><td rowspan=1 colspan=1>54/54 (100%)</td><td rowspan=1 colspan=1>54/54 (100%)</td><td rowspan=1 colspan=1>54/54 (100%)</td></tr><tr><td rowspan=1 colspan=1>Ceftazidime</td><td rowspan=1 colspan=1>92/93 (98.9%)</td><td rowspan=1 colspan=1>91/93 (97.8%)</td><td rowspan=1 colspan=1>92/93 (98.9%)</td><td rowspan=1 colspan=1>91/93 (97.8%)</td></tr><tr><td rowspan=1 colspan=1>Ceftazidime-Avibactam</td><td rowspan=1 colspan=1>47/47 (100%)</td><td rowspan=1 colspan=1>43/47 (91.5%)</td><td rowspan=1 colspan=1>47/47 (100%)</td><td rowspan=1 colspan=1>43/47 (91.5%)</td></tr><tr><td rowspan=1 colspan=1>Eravacycline</td><td rowspan=1 colspan=1>103/103 (100%)</td><td rowspan=1 colspan=1>99/103 (96.1%)</td><td rowspan=1 colspan=1>103/103 (100%)</td><td rowspan=1 colspan=1>99/103 (96.1%)</td></tr><tr><td rowspan=1 colspan=1>Gentamicin</td><td rowspan=1 colspan=1>116/121 (95.9%)</td><td rowspan=1 colspan=1>116/121 (95.9%)</td><td rowspan=1 colspan=1>116/121 (95.9%)</td><td rowspan=1 colspan=1>116/121(95.9%)</td></tr><tr><td rowspan=1 colspan=1>Imipenem-Relebactam</td><td rowspan=1 colspan=1>72/76 (94.7%)</td><td rowspan=1 colspan=1>72/76 (94.7%)</td><td rowspan=1 colspan=1>72/76 (94.7%)</td><td rowspan=1 colspan=1>72/76 (94.7%)</td></tr><tr><td rowspan=1 colspan=1>Levofloxacin</td><td rowspan=1 colspan=1>179/181 (98.9%)</td><td rowspan=1 colspan=1>174/181 (96.1%)</td><td rowspan=1 colspan=1>179/181 (98.9%)</td><td rowspan=1 colspan=1>174/181 (96.1%)</td></tr><tr><td rowspan=1 colspan=1>Meropenem</td><td rowspan=1 colspan=1>57/58 (98.3%)</td><td rowspan=1 colspan=1>56/58 (96.6%)</td><td rowspan=1 colspan=1>57/58 (98.3%)</td><td rowspan=1 colspan=1>56/58 (96.6%)</td></tr><tr><td rowspan=1 colspan=1>Meropenem-Vaborbactam</td><td rowspan=1 colspan=1>45/47 (95.7%)</td><td rowspan=1 colspan=1>43/47 (91.5%)</td><td rowspan=1 colspan=1>45/47 (95.7%)</td><td rowspan=1 colspan=1>43/47 (91.5%)</td></tr><tr><td rowspan=1 colspan=1>Piperacillin-Tazobactam</td><td rowspan=1 colspan=1>54/56 (96.4%)</td><td rowspan=1 colspan=1>54/56 (96.4%)</td><td rowspan=1 colspan=1>54/56 (96.4%)</td><td rowspan=1 colspan=1>54/56 (96.4%)</td></tr><tr><td rowspan=1 colspan=1>Trimethoprim-Sulfamethoxazole</td><td rowspan=1 colspan=1>62/65 (95.4%)</td><td rowspan=1 colspan=1>61/65 (93.8%)</td><td rowspan=1 colspan=1>62/65 (95.4%)</td><td rowspan=1 colspan=1>61/65 (93.8%)</td></tr></table>

a In instances where the original study had lower than the required number, supplemental testing was conducted and data collated with original data.

2. Linearity: Not applicable

3. Analytical Specificity/Interference: Not Applicable

4. Assay Reportable Range: Not applicable

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

Quality Control Testing. The Selux AST System software contains QC Sets (A, B, C) such that when the Gram-Negative Panel is selected, the system will indicate the appropriate QC strains to be prepared for testing. CLSI-recommended QC strains and expected QC ranges for use with the Gram-Negative Panel are summarized in Table 4, which also includes the designation of the QC set as appropriate for each antimicrobial. Notably, QC Set A comprises gram-positive ATCC QC organisms which is acceptable to use for QC testing of the Gram-Negative Panel provided that QC is run concurrently with Set B and/or C, which comprise gram-negative ATCC QC organisms. This is necessary because the metabolic assay in the Selux AST System utilizes an additional biochemical reagent, an electron transfer agent, exclusively with gram-negative organisms. The following QC reporting scheme is included in the device labeling (and is supported by software information) to ensure that gram-negative organisms will be processed correctly by the Selux AST System:

Gram-Negative Panel QC failure when testing gram-positive QC organisms: clinical results should not be reported for the antimicrobial(s) in which QC failed but may be reported for the antimicrobials for which QC passed. • Gram-Negative Panel QC failure when testing gram-negative QC organisms: o If all gram-negative organisms fail QC: all QC results (including those when testing gram-positive organisms) should be considered failed and clinical results should not be reported for any antimicrobial. o If one (or fewer than all) gram-negative organisms fail QC: clinical results should not be reported for the antimicrobial(s) in which QC failed but may be reported for the antimicrobials for which QC passed (including those when testing grampositive organisms).

Table 4. CLSI-Recommended QC Organisms for Gram-Negative Panel   

<table><tr><td colspan="1" rowspan="1">Antimicrobial</td><td colspan="1" rowspan="1">Abbreviation</td><td colspan="1" rowspan="1">QC Set</td><td colspan="1" rowspan="1">QC Strain</td><td colspan="1" rowspan="1">Expected QC Range(μg/mL)</td></tr><tr><td colspan="1" rowspan="1">Amikacin</td><td colspan="1" rowspan="1">AMK</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">ATCC 29213 a</td><td colspan="1" rowspan="1">1-4</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin-Clavulanate</td><td colspan="1" rowspan="1">AMC</td><td colspan="1" rowspan="1">B</td><td colspan="1" rowspan="1">ATCC 700603</td><td colspan="1" rowspan="1">4-16</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">AMP</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">ATCC 25922</td><td colspan="1" rowspan="1">2-8</td></tr><tr><td colspan="1" rowspan="1">Ampicillin-Sulbactam</td><td colspan="1" rowspan="1">SAM</td><td colspan="1" rowspan="1">B</td><td colspan="1" rowspan="1">ATCC 700603</td><td colspan="1" rowspan="1">8-32</td></tr><tr><td colspan="1" rowspan="1">Aztreonam</td><td colspan="1" rowspan="1">ATM</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">ATCC 25922</td><td colspan="1" rowspan="1">0.06-0.25</td></tr><tr><td colspan="1" rowspan="1">Cefazolin</td><td colspan="1" rowspan="1">CFZ</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">ATCC 25922</td><td colspan="1" rowspan="1">1-4</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">FEP</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">ATCC 29213 a</td><td colspan="1" rowspan="1">1-4</td></tr><tr><td colspan="1" rowspan="1">Cefoxitin</td><td colspan="1" rowspan="1">FOX</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">ATCC 25922</td><td colspan="1" rowspan="1">2-8</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">CAZ</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">ATCC 29213 a</td><td colspan="1" rowspan="1">4-16</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-Avibactam</td><td colspan="1" rowspan="1">CZA</td><td colspan="1" rowspan="1">B</td><td colspan="1" rowspan="1">ATCC 700603</td><td colspan="1" rowspan="1">0.25-2</td></tr><tr><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">CRO</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">ATCC 29213 a</td><td colspan="1" rowspan="1">1-8</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">CIP</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">ATCC 29213 a</td><td colspan="1" rowspan="1">0.12-0.5</td></tr><tr><td colspan="1" rowspan="1">Eravacycline</td><td colspan="1" rowspan="1">ERV</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">ATCC 25922</td><td colspan="1" rowspan="1">0.016-0.12</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">ETP</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">ATCC 29213 a</td><td colspan="1" rowspan="1">0.06-0.25</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">GEN</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">ATCC 29212 a</td><td colspan="1" rowspan="1">4-16</td></tr><tr><td colspan="1" rowspan="1">Imipenem</td><td colspan="1" rowspan="1">IMP</td><td colspan="1" rowspan="1">B</td><td colspan="1" rowspan="1">ATCC 700603</td><td colspan="1" rowspan="1">0.06-0.5</td></tr><tr><td colspan="1" rowspan="1">Imipenem-Relebactam</td><td colspan="1" rowspan="1">IMR</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">ATCC BAA-2814</td><td colspan="1" rowspan="1">0.06-0.5</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">LVX</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">ATCC 29212 a</td><td colspan="1" rowspan="1">0.25-2</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">MEM</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">ATCC 29212 a</td><td colspan="1" rowspan="1">2-8</td></tr><tr><td colspan="1" rowspan="1">Meropenem-Vaborbactam</td><td colspan="1" rowspan="1">MEV</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">ATCC BAA-2814</td><td colspan="1" rowspan="1">0.12-0.5</td></tr><tr><td colspan="1" rowspan="1">Minocycline</td><td colspan="1" rowspan="1">MIN</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">ATCC 29212 a</td><td colspan="1" rowspan="1">1-4</td></tr><tr><td colspan="1" rowspan="1">Piperacillin-Tazobactam</td><td colspan="1" rowspan="1">TZP</td><td colspan="1" rowspan="1">B</td><td colspan="1" rowspan="1">ATCC 700603</td><td colspan="1" rowspan="1">8-32</td></tr><tr><td colspan="1" rowspan="1">Tobramycin</td><td colspan="1" rowspan="1">TOB</td><td colspan="1" rowspan="1">A</td><td colspan="1" rowspan="1">ATCC 29212 a</td><td colspan="1" rowspan="1">8-32</td></tr><tr><td colspan="1" rowspan="1">Trimethoprim-Sulfamethoxazole</td><td colspan="1" rowspan="1">SXT</td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">ATCC 25922</td><td colspan="1" rowspan="1">0.12-0.5b</td></tr></table>

a Set A comprises gram-positive ATCC QC organisms which is acceptable to use for QC testing of the Gram-Negative Comprehensive panel provided that QC is run concurrently with Set B and/or C, which comprise gram-negative ATCC QC organisms. This is necessary because the metabolic assay in the Selux AST System utilizes an additional biochemical reagent, an electron transfer agent, exclusively with gram-negative organisms. This ensures that gram-negative organisms will be processed correctly by the Selux AST System. b Expected QC range for SXT in CLSI M100 is $\le 0 . 5$ ; Selux AST reporting range for SXT is ${ \le } 0 . 1 2$ to $2 3 2 \mu \mathrm { g / m L }$ . Selux MIC results of $\leq 0 . 5 ~ \mu \mathrm { g / m L }$ were considered acceptable.

Quality control testing was performed each day that testing was conducted. CLSIrecommended QC strains for each antimicrobial (described in Table 4) were tested a sufficient number of times (i.e., at least 20 times/site) at each testing site using the Selux AST System. QC testing of the broth microdilution reference method was performed at a single, central site. In some cases, the site used CLSI-recommended QC organisms that were different from QC organisms tested with the Selux AST System. This is noted in Table 5.

QC expected ranges and results for the Selux AST System with Gram-Negative panel are summarized in Table 5. For all antimicrobials, greater than $9 5 \%$ of results were within the expected range, which is acceptable.

Due to an administrative error, reference data for minocycline and tobramycin was not previously included in Table 5. This data is included in the updated table for both minocycline and tobramycin testing of E. coli ATCC 25922.

Table 5. QC Results for the Selux AST System Assay with Gram Negative Panel   

<table><tr><td colspan="1" rowspan="2">Antimicrobial</td><td colspan="1" rowspan="2">QC Strain</td><td colspan="1" rowspan="2">ExpectedRange (μg/mL)</td><td colspan="2" rowspan="1">No. in Range (%)</td></tr><tr><td colspan="1" rowspan="1">Reference</td><td colspan="1" rowspan="1">Selux</td></tr><tr><td colspan="1" rowspan="1">Amikacin</td><td colspan="1" rowspan="1">S. aureus ATCC 29213</td><td colspan="1" rowspan="1">1-4</td><td colspan="1" rowspan="1">56/56 (100)</td><td colspan="1" rowspan="1">218/219 (99.5)</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">K. pneumoniae ATCC 700603a</td><td colspan="1" rowspan="1">≥128c</td><td colspan="1" rowspan="1">4747 (100)</td><td colspan="1" rowspan="1">219/221 (99.1)</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin-Clavulanate</td><td colspan="1" rowspan="1">K. pneumoniae ATCC 700603</td><td colspan="1" rowspan="1">4-16</td><td colspan="1" rowspan="1">49/50 (98.0)</td><td colspan="1" rowspan="1">211/221 (95.5)</td></tr><tr><td colspan="1" rowspan="2">Ampicillin</td><td colspan="1" rowspan="1">E. coli ATCC 25922</td><td colspan="1" rowspan="1">2-8</td><td colspan="1" rowspan="1">47/48 (97.9)</td><td colspan="1" rowspan="1">210/210 (100)</td></tr><tr><td colspan="1" rowspan="1">K. pneumoniae ATCC 700603a</td><td colspan="1" rowspan="1">≥128c</td><td colspan="1" rowspan="1">50/50 (100)</td><td colspan="1" rowspan="1">219/221 (99.1)</td></tr><tr><td colspan="1" rowspan="1">Ampicillin-Sulbactam</td><td colspan="1" rowspan="1">K. pneumoniae ATCC 700603</td><td colspan="1" rowspan="1">8-32</td><td colspan="1" rowspan="1">46/47 (97.9)</td><td colspan="1" rowspan="1">221/221 (100)</td></tr><tr><td colspan="1" rowspan="1">Aztreonam</td><td colspan="1" rowspan="1">E. coli ATCC 25922</td><td colspan="1" rowspan="1">0.06-0.25</td><td colspan="1" rowspan="1">56/57 (98.2)</td><td colspan="1" rowspan="1">210/210 (100)</td></tr><tr><td colspan="1" rowspan="1">Cefazolin</td><td colspan="1" rowspan="1">E. coli ATCC 25922</td><td colspan="1" rowspan="1">1-4</td><td colspan="1" rowspan="1">53/53 (100)</td><td colspan="1" rowspan="1">210/210 (100)</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">S. aureus ATCC 29213</td><td colspan="1" rowspan="1">1-4</td><td colspan="1" rowspan="1">54/55 (98.2)</td><td colspan="1" rowspan="1">218/219 (99.5)</td></tr><tr><td colspan="1" rowspan="1">Cefoxitin</td><td colspan="1" rowspan="1">E. coli ATCC 25922</td><td colspan="1" rowspan="1">2-8</td><td colspan="1" rowspan="1">45/46 (97.8)</td><td colspan="1" rowspan="1">209/210 (99.5)</td></tr><tr><td colspan="1" rowspan="3">Ceftazidime</td><td colspan="1" rowspan="1">S. aureus ATCC 29213</td><td colspan="1" rowspan="1">4-16</td><td colspan="1" rowspan="1">NT</td><td colspan="1" rowspan="1">217/219 (99.1)</td></tr><tr><td colspan="1" rowspan="1">E. coli ATCC 25922b</td><td colspan="1" rowspan="1">0.06-0.5</td><td colspan="1" rowspan="1">56/57 (98.2)</td><td colspan="1" rowspan="1">NT</td></tr><tr><td colspan="1" rowspan="1">K. pneumoniae ATCC 700603a</td><td colspan="1" rowspan="1">16-64</td><td colspan="1" rowspan="1">66/66 (100)</td><td colspan="1" rowspan="1">218/221 (98.6)</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-Avibactam</td><td colspan="1" rowspan="1">K. pneumoniae ATCC 700603</td><td colspan="1" rowspan="1">0.25-2</td><td colspan="1" rowspan="1">59/59 (100)</td><td colspan="1" rowspan="1">221/221 (100)</td></tr><tr><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">S. aureus ATCC 29213</td><td colspan="1" rowspan="1">1-8</td><td colspan="1" rowspan="1">45/49 (97.8)</td><td colspan="1" rowspan="1">218/219 (99.5)</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">S. aureus ATCC 29213</td><td colspan="1" rowspan="1">0.12-0.5</td><td colspan="1" rowspan="1">57/58 (98.3)</td><td colspan="1" rowspan="1">218/219 (99.5)</td></tr><tr><td colspan="1" rowspan="1">Eravacycline</td><td colspan="1" rowspan="1">E. coli ATCC 25922</td><td colspan="1" rowspan="1">0.016-0.12</td><td colspan="1" rowspan="1">49/49 (100)</td><td colspan="1" rowspan="1">210/210 (100)</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">S. aureus ATCC 29213</td><td colspan="1" rowspan="1">0.06-0.25</td><td colspan="1" rowspan="1">51/51 (100)</td><td colspan="1" rowspan="1">217/219 (99.1)</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">E. faecalis ATCC 29212</td><td colspan="1" rowspan="1">4-16</td><td colspan="1" rowspan="1">51/53 (96.2)</td><td colspan="1" rowspan="1">216/217 (99.5)</td></tr><tr><td colspan="1" rowspan="2">Imipenem</td><td colspan="1" rowspan="1">K. pneumoniae ATCC 700603</td><td colspan="1" rowspan="1">0.06-0.5</td><td colspan="1" rowspan="1">64/64 (100)</td><td colspan="1" rowspan="1">221/221 (100)</td></tr><tr><td colspan="1" rowspan="1">K. pneumoniae ATCC BAA-2814a</td><td colspan="1" rowspan="1">16-64</td><td colspan="1" rowspan="1">65/65 (100)</td><td colspan="1" rowspan="1">210/210 (100)</td></tr><tr><td colspan="1" rowspan="1">Imipenem-Relebactam</td><td colspan="1" rowspan="1">K. pneumoniae ATCC BAA-2814</td><td colspan="1" rowspan="1">0.06-0.5</td><td colspan="1" rowspan="1">65/65 (100)</td><td colspan="1" rowspan="1">207/210 (98.6)</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">E. faecalis ATCC 29212</td><td colspan="1" rowspan="1">0.25-2</td><td colspan="1" rowspan="1">38/40 (95.0)</td><td colspan="1" rowspan="1">89/90 (98.9)</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">E. faecalis ATCC 29212</td><td colspan="1" rowspan="1">2-8</td><td colspan="1" rowspan="1">55/56 (98.2)</td><td colspan="1" rowspan="1">217/217 (100)</td></tr><tr><td colspan="1" rowspan="1">Meropenem-Vaborbactam</td><td colspan="1" rowspan="1">K. pneumoniae ATCC BAA-2814</td><td colspan="1" rowspan="1">0.12-0.5</td><td colspan="1" rowspan="1">48/49 (98.0)</td><td colspan="1" rowspan="1">204/210 (97.1)</td></tr><tr><td colspan="1" rowspan="2">Minocycline</td><td colspan="1" rowspan="1">E. faecalis ATCC 29212</td><td colspan="1" rowspan="1">1-4</td><td colspan="1" rowspan="1">NT</td><td colspan="1" rowspan="1">216/217 (99.5)</td></tr><tr><td colspan="1" rowspan="1">E. coli ATCC 25922b</td><td colspan="1" rowspan="1">0.25-1</td><td colspan="1" rowspan="1">43/44 (97.7)</td><td colspan="1" rowspan="1">NT</td></tr><tr><td colspan="1" rowspan="1">Piperacillin-Tazobactam</td><td colspan="1" rowspan="1">K. pneumoniae ATCC 700603</td><td colspan="1" rowspan="1">8-32</td><td colspan="1" rowspan="1">66/66 (100)</td><td colspan="1" rowspan="1">221/221 (100)</td></tr><tr><td colspan="1" rowspan="2">Tobramycin</td><td colspan="1" rowspan="1">E. faecalis ATCC 29212</td><td colspan="1" rowspan="1">8-32</td><td colspan="1" rowspan="1">NT</td><td colspan="1" rowspan="1">211/217 (97.2)</td></tr><tr><td colspan="1" rowspan="1">E. coli ATCC 25922b</td><td colspan="1" rowspan="1">0.25-1</td><td colspan="1" rowspan="1">52/53 (98.1)</td><td colspan="1" rowspan="1">NT</td></tr><tr><td colspan="1" rowspan="1">Trimethoprim-Sulfamethoxazole</td><td colspan="1" rowspan="1">E. coli ATCC 25922</td><td colspan="1" rowspan="1">0.12-0.5b</td><td colspan="1" rowspan="1">44/100 (100)</td><td colspan="1" rowspan="1">208/210 (99.0)</td></tr></table>

NT: Not tested a Tested to confirm the integrity of the QC strain for testing with the beta-lactam/beta-lactam-inhibitor combination antimicrobial. b BMD reference method testing was performed at a single, central site which utilized their standard, CLSI-recommended QC organisms. c Expected QC range in CLSI M100 is ${ > } 1 2 8$ ; highest concentration of Amoxicillin and Ampicillin on the Selux AST result panel is 128 $\mu \mathrm { g / m L }$ . Selux MIC results of $\geq 1 2 8 \ \mu \mathrm { g / m L }$ were considered acceptable.

Inoculum Density Check: Refer to the K211759 decision summary for description and results since studies were performed concurrently.

Device Failure: Refer to the K211759 decision summary for description and results since studies were performed concurrently.

Growth Failure Rate: There were 13 growth failures (13/1401 tests $= 0 . 9 3 \%$ ) when using the Gram-Negative Panel on the Selux AST System. All samples that generated Selux results also generated reference method results.

Purity Check: Purity plates were prepared from the inoculum suspensions of every sample tested. AST results were only reported for pure isolates; data generated from plates that generated multiple colony morphologies was excluded from analyses.

6. Detection Limit:

Not Applicable

7. Assay Cut-Off: Not Applicable

# B Comparison Studies:

1. Method Comparison with Predicate Device:

Clinical performance testing on the Selux AST System was initially performed at three U.S. test sites (2 external, 1 internal). For instances in which testing was required to supplement existing data from the original study and support specific claims, testing was performed on three Selux AST System instruments at two testing sites.

Performance was evaluated using contemporary and stock frozen clinical isolates as well as challenge isolates, which were selected for their resistance profiles. Clinical isolates of nonfastidious bacteria were recovered from cultures of clinical specimens (e.g., blood, stool, urine, respiratory, wound, aspirates) from diverse geographic locations across the U.S.

Contemporary frozen isolates were defined as isolates that had been collected and frozen within six months of testing while stock frozen isolates were tested six or more months after collection.

A total of 1401 clinical (426 contemporary and 975 stock) and 222 challenge isolates from 12 Enterobacterales species, Acinetobacter baumannii complex, and Pseudomonas aeruginosa were tested to evaluate the Selux AST System performance for 24 antimicrobials using the Selux Gram-Negative panel. Depending on the spectrum of activity, breakpoints and the claimed organisms (species/group) for each antimicrobial on the panel, the number of datapoints for the various antimicrobial-organisms tested varied and ranged from 165 (e.g. $P$ . aeruginosa/Imipenem-Relebactam) to 977 (e.g. Enterobacterales/Ertapenem). Selux results were compared to the modal value of triplicate broth microdilution reference results performed at an independent reference laboratory.

Performance was determined generally based on criteria outlined in the Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems including essential agreement (EA), categorical agreement (CA), and categorical errors (minor, major and very major errors). EA was calculated as the percentage of Selux MIC results that were within plus or minus one serial two-fold dilution of the reference result. CA was calculated as the percentage of Selux interpretive results (S/I/R) that were identical to the interpretive results of the reference result. EA of evaluable results (on-scale Selux and reference results or results in which an off-scale result was at least two doubling dilutions from the on-scale result) were also calculated. Performance was considered acceptable if the EA and CA were $2 9 0 \%$ , major error rate was $\leq 3 \%$ , and very major error rate was $\leq 2 \%$ .

A trending analysis using combined clinical and challenge isolate results was also conducted to evaluate antimicrobial-organism combinations for which Selux MIC results were determined to be one or more doubling dilutions lower or higher than the reference result. MIC results that were off-scale for both the reference and Selux were not considered in the trending analysis. Antimicrobial-organism combinations for which the difference between the percentage of isolates with higher or lower MIC values was $\ge 3 0 \%$ with a statistically

significant confidence interval were considered to have evidence of trending and is addressed in the labeling.

A high-level summary of the Selux AST System performance using the Gram-Negative Panel is described below for each antimicrobial and indicated species. Complete details and results including EA, CA and error rate analyses are summarized in Table 6 and trending analyses are summarized in Table 7.

Amikacin. A total of 111 A. baumannii isolates were evaluated with amikacin. The combined results from clinical and challenge isolate testing demonstrated an EA of $5 5 . 0 \%$ and CA of $8 6 . 5 \%$ , which is not acceptable. There were 6 minor, 8 major $( 8 / 8 0 = 1 0 \% )$ ) and 1 very major $1 / 2 5 = 4 \%$ ) errors, which is not acceptable. Due to the unacceptable performance for $A$ . baumannii, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation is included in the device labeling to restrict reporting of $A$ . baumannii due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

• Amikacin: Acinetobacter baumannii

A total of $1 6 5 ~ P _ { \cdot }$ . aeruginosa isolates were evaluated with amikacin. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 0 . 9 \%$ and CA of $9 8 . 2 \%$ . There were 3 minor, 0 major and 0 very major errors. Overall, performance is acceptable.

Analysis of trending indicated that MIC values for $P _ { - }$ . aeruginosa tended to be one doubling dilution lower than the reference MIC value. The following statement is included in the device labeling as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution lower than the reference MIC value:

• Amikacin: Pseudomonas aeruginosa

Amoxicillin-Clavulanate. A total of 593 Enterobacterales isolates (indicated species: $1 7 9 E$ . coli, $4 8 K .$ . oxytoca, $1 4 2 K .$ . pneumoniae, $8 8 ~ P .$ . mirabilis; non-indicated species: $7 4 ~ C .$ . koseri, $6 2 P .$ . vulgaris) were evaluated with amoxicillin-clavulanate. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 3 . 3 \%$ and CA of $9 2 . 8 \%$ . There were 37 minor, 5 major and 1 very major errors. When evaluating results by individual species, $E$ . coli had a CA of $8 8 . 7 \%$ due to 17 minor, 1 major and 0 very major errors which was determined to be acceptable since the majority of categorical errors were minor and the EA of evaluable results was good $( 9 6 . 5 \% )$ . $P _ { - }$ . mirabilis had one very major error ( $1 / 8 =$ $1 6 . 7 \% )$ , which was considered a random error due to the limited number of resistant isolates tested.

Analysis of trending indicated that MIC values for $K .$ . pneumoniae tended to be one doubling dilution lower than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution lower than the reference MIC value:

• Amoxicillin-Clavulanate: Klebsiella pneumoniae

Ampicillin. A total of 254 Enterobacterales isolates ( $1 6 5 E$ . coli, $8 9 P$ . mirabilis) were evaluated with ampicillin. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 4 . 9 \%$ and CA of $9 8 . 8 \%$ . There was 1 minor, 1 major and 1 very major error. When evaluating results by individual species, $P .$ . mirabilis had 1 major error $( 1 / 6 0 = 1 . 7 \% )$ and 1 very major error $1 / 2 6 = 3 . 8 \%$ ) at a Selux MIC value of $2 ~ { \mu \mathrm { g / m L } }$ which represents $4 . 5 \%$ (4/89) of results with this drug/organism combination. The following limitation is included in the device labeling to address the very major error:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

• Ampicillin: Proteus mirabilis when the Selux MIC is $2 ~ { \mu \mathrm { g / m L } }$ due to one very major error

Analysis of trending indicated that MIC values for $E$ . coli tended to be one doubling dilution lower than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution lower than the reference MIC value:

• Ampicillin: Escherichia coli

Ampicillin-Sulbactam. A total of $1 2 3 A .$ . baumannii isolates were evaluated with ampicillinsulbactam. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 1 . 9 \%$ and CA of $9 2 . 7 \%$ . There were 6 minor, 2 major and 1 very major error. Overall, performance is acceptable.

A total of 574 Enterobacterales isolates ( $2 0 4 E .$ . coli, $2 9 K .$ oxytoca, $1 1 6 K .$ . pneumoniae, 75 $M .$ . morganii, $8 8 P .$ . mirabilis, $6 2 P .$ . vulgaris) were evaluated with ampicillin-sulbactam. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 6 . 9 \%$ and CA of $8 3 . 5 \%$ . There were 90 minor, 5 major and 0 very major errors. When evaluating results by individual species, $K .$ . oxytoca and $P$ . mirabilis each had CA $- 9 0 \%$ which was considered acceptable since all of the categorical errors were minor and the EA of evaluable results was good $( > 9 5 \% )$ . $P$ . vulgaris had a CA of $4 5 . 2 \%$ due to 31 minor errors as well as 3 major errors $( 3 / 4 3 = 7 . 0 \% )$ ) at a Selux MIC value of $3 2 ~ \mu \mathrm { g / m L }$ which represents $9 . 7 \%$ (6/62) of results with this drug/organism combination. $M .$ morganii had a CA of $72 \%$ due to 19 minor and 2 major errors $( 2 / 4 = 5 0 \% )$ , which is not acceptable. Due to the unacceptable performance for $M .$ morganii, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation is included in the device labeling address the $P _ { - }$ . vulgaris major errors and restrict reporting of $M .$ . morganii due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Ampicillin-Sulbactam: Morganella morganii; Proteus vulgaris when the Selux MIC is $3 2 ~ \mu \mathrm { g / m L }$ due to 3 major errors

A limitation statement is included in the device labeling to address the lack of testing with resistant $P$ . vulgaris isolates.

Analysis of trending indicated that MIC values for $K .$ . oxytoca tended to be one doubling dilution lower than the reference MIC value while MIC values for $P _ { - }$ . vulgaris tended to be one doubling dilution higher than the reference MIC value. The following statements are included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution lower than the reference MIC value:

Ampicillin-Sulbactam: Klebsiella oxytoca

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Ampicillin-Sulbactam: Proteus vulgaris

Aztreonam. A total of 183 Enterobacterales isolates ( $1 8 3 E$ . coli) were evaluated with aztreonam. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 7 . 8 \%$ and CA of $9 7 . 3 \%$ . There were 5 minor, 0 major and 0 very major errors. Overall, performance is acceptable.

A total of $2 1 9 P .$ . aeruginosa isolates were evaluated with aztreonam. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 1 . 3 \%$ and CA of $8 7 . 7 \%$ . There were 20 minor, 3 major $3 / 1 5 8 = 1 . 9 \%$ ) and 4 very major $4 / 4 8 = 8 . 3 \%$ ) errors. Due to the unacceptable performance for $P .$ . aeruginosa, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation is included in the device labeling to restrict reporting of $P .$ . aeruginosa due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

• Aztreonam: Pseudomonas aeruginosa

Cefazolin. A total of 412 Enterobacterales isolates (indicated species: 177 E. coli, $1 1 5 K .$ . pneumoniae, $6 6 P .$ . mirabilis; non-indicated species: $5 4 ~ C .$ . koseri) were evaluated with cefazolin. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 4 . 2 \%$ and CA of $7 4 . 8 \%$ . There were 102 minor, 1 major and 1 very major errors. When evaluating results by individual species, $E .$ . coli and $K .$ . pneumoniae each had CA $- 9 0 \%$ which was considered acceptable since most of the categorical errors were minor and the EA of evaluable results was good $( > 9 0 \% )$ . $P _ { - }$ . mirabilis had an EA of $8 6 . 4 \%$ and an EA of evaluable results of $8 4 . 8 \%$ (50/59), which is not acceptable. Due to the unacceptable performance for $P .$ . mirabilis, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation statement is included in the device labeling to restrict reporting of $P$ . mirabilis due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combinations:

• Cefazolin: Proteus mirabilis

Analysis of trending indicated that MIC values for C. koseri, E. coli and K. pneumoniae tended to be one doubling dilution lower than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution lower than the reference MIC value:

• Cefazolin: Citrobacter koseri, Escherichia coli, Klebsiella pneumoniae

Cefepime. A total of 956 Enterobacterales isolates (77 C. freundii complex, $7 4 ~ C .$ koseri, 77 $E$ . cloacae complex, $1 7 0 E .$ . coli, $5 2 K .$ . aerogenes, $2 9 K .$ . oxytoca, $1 1 1 K .$ . pneumoniae, $7 5 M .$ morganii, $8 8 ~ P .$ . mirabilis, $1 0 0 P .$ . vulgaris, $1 0 3 \ : S .$ marcescens) were evaluated with cefepime. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 4 . 8 \%$ and CA of $9 6 . 0 \%$ . There were 26 minor, 10 major and 2 very major errors. When evaluating results by individual species, $M .$ morganii had 1 very major error $1 / 1 = 1 0 0 \%$ ) and $P _ { - }$ . vulgaris had 1 very major error $( 1 / 2 = 5 0 \%$ ), which were considered random errors due to the insufficient number of resistant isolates tested. $K .$ . aerogenes had 2 major errors $( 2 / 5 1 = 3 . 9 \% )$ at Selux MIC values of $\geq 6 4 ~ \mu \mathrm { g / m L }$ which represents $5 . 8 \%$ (3/52) of results with this drug/organism combination. The following limitation is included in the device labeling to address the major errors:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Cefepime: Klebsiella aerogenes when the Selux MIC is to $\geq 6 4 ~ \mu \mathrm { g / m L }$ due to two major errors

A total of $2 1 5 { \ : } P .$ . aeruginosa isolates were evaluated with cefepime. The combined results from clinical and challenge isolate testing demonstrated an EA of $8 7 . 4 \%$ and CA of $8 6 . 8 \%$ . There were 0 minor, 13 major ( $1 3 / 1 7 8 = 7 . 3 \%$ and 7 very major $( 7 / 3 7 = 1 8 . 9 \% )$ errors. Due to the lack of an intermediate interpretive criterion, further analysis of the errors was performed and adjustments were made by considering the MIC values of the errors compared to the reference MIC value. Nine of the 13 major errors and 6 of the 7 very major errors had an MIC value that was in essential agreement with the reference MIC value. Therefore, the adjusted major error rate is $2 . 2 \%$ (4/178), which is acceptable. However, the adjusted very major error rate is $2 . 7 \%$ (1/37) which is not acceptable. Due to the unacceptable performance for $P .$ . aeruginosa, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation is included in the device labeling to restrict reporting of $P .$ . aeruginosa due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Cefepime: Pseudomonas aeruginosa

A limitation statement is included in the device labeling to address the lack of testing with resistant $K .$ . aerogenes, M. morganii, P. vulgaris and S. marcescens isolates.

Analysis of trending indicated that MIC values for C. freundii, C. koseri, E. cloacae, E. coli, K. aerogenes, K. oxytoca, M. morganii, $P .$ . mirabilis, $P .$ . vulgaris, S. marcescens tended to be one doubling dilution higher than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Cefepime: Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens

Cefoxitin. A total of 637 Enterobacterales isolates (indicated species:168 $E$ . coli, $2 9 K .$ . oxytoca, $1 3 3 K .$ . pneumoniae, $6 4 M .$ morganii, $8 9 P .$ . mirabilis, $1 0 0 P .$ . vulgaris; non-indicated species: $5 4 ~ C .$ . koseri) were evaluated with cefoxitin. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 2 . 3 \%$ and CA of $8 0 . 2 \%$ . There were 114 minor, 9 major and 3 very major errors. When evaluating results by individual species, $K .$ oxytoca and $M .$ morganii had CA of ${ < 9 0 \% }$ which was considered acceptable since most of the categorical errors were minor and the EA of evaluable results was good $( > 9 0 \% )$ . $P$ . mirabilis had a CA of $8 8 . 8 \%$ due to 6 minor, 2 major $( 2 / 7 5 = 2 . 7 \% )$ and 2 very major $( 2 / 7 =$ $2 8 . 6 \% )$ errors, which is not acceptable. $P .$ . vulgaris had an EA of $8 6 \%$ and a CA of $53 \%$ due to 46 minor errors and 1 major error $( 1 / 5 3 = 1 . 9 \% )$ ), which is not acceptable. Due to the unacceptable performance for $P .$ . mirabilis and $P$ . vulgaris, these drug/organism combinations are not indicated for use with the Selux AST System. The following limitation is included in the device labeling to restrict reporting of $P .$ . mirabilis and $P _ { - }$ . vulgaris due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Cefoxitin: Proteus mirabilis, Proteus vulgaris

A limitation statement is included in the device labeling to address the lack of testing with resistant $K .$ . oxytoca and $P$ . vulgaris isolates.

There was no evidence of trending observed with any indicated species with cefoxitin.

Ceftazidime. A total of 127 A. baumannii isolates were evaluated with ceftazidime. The combined results from clinical and challenge isolate testing demonstrated an EA of $8 6 . 6 \%$ and CA of $9 4 . 5 \%$ . There were 7 minor, 0 major and 0 very major error. In addition, the EA of evaluable results was $8 1 . 5 \%$ (75/92). Due to the unacceptable performance for $A$ . baumannii, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation is included in the device labeling to restrict reporting of $A$ . baumannii due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Ceftazidime: Acinetobacter baumannii

A total of 787 Enterobacterales isolates ( $6 4 ~ C .$ . freundii, $5 5 ~ C .$ . koseri, $8 4 E .$ . cloacae, $1 8 6 E$ . coli, $3 6 K .$ . aerogenes, $2 9 K .$ . oxytoca, $1 4 5 \ K$ . pneumoniae, $6 6 P$ . mirabilis, $5 5 ~ P .$ . vulgaris, 67 S. marcescens) were evaluated with ceftazidime. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 5 . 6 \%$ and CA of $9 6 . 4 \%$ . There were 26 minor, 1 major and 1 very major errors. Overall, performance is acceptable.

A total of $2 2 4 P .$ . aeruginosa isolates were evaluated with ceftazidime. The combined results from clinical and challenge isolate testing demonstrated an EA of $8 8 . 0 \%$ and CA of $9 3 . 3 \%$ . There were 9 major $( 9 / 1 7 8 = 5 . 1 \% )$ and 6 very major $( 6 / 4 6 = 1 3 \%$ errors. Due to the lack of an intermediate interpretive criterion, further analysis of the errors was performed and adjustments were made by considering the MIC values of the errors compared to the reference MIC value. One of the 9 major errors and 1 of the 6 very major errors had an MIC value that was in essential agreement with the reference MIC value. Therefore, the adjusted major error rate is $4 . 5 \%$ (8/177) and the adjusted very major error rate is $1 0 . 9 \%$ (5/46), which is not acceptable. Due to the unacceptable performance for $P$ . aeruginosa, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation is included in the device labeling to restrict reporting of $P _ { - }$ . aeruginosa due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Ceftazidime: Pseudomonas aeruginosa

Analysis of trending indicated that MIC values for $C .$ . freundii complex, C. koseri, $E$ . cloacae, K. aerogenes, K. oxytoca, K. pneumoniae, $P$ . mirabilis, $P .$ . vulgaris, and $S .$ marcescens tended to be one doubling dilution higher than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Ceftazidime: Citrobacter freundii complex, Citrobacter koseri, Enterobacter cloacae, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Serratia marcescens

Ceftazidime-avibactam. A total of 815 Enterobacterales isolates (61 C. freundii, $5 4 ~ C .$ . koseri, $7 5 E$ . cloacae, $1 7 0 E .$ . coli, $5 2 K .$ . aerogenes, $2 8 K .$ . oxytoca, $1 2 6 K .$ . pneumoniae, $6 2 M .$ morganii, $6 6 P .$ . mirabilis, $5 5 ~ P .$ . vulgaris, $6 6 S .$ . marcescens) were evaluated with ceftazidime-avibactam. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 7 . 3 \%$ and CA of $9 9 . 4 \%$ . There were 5 major and 0 very major errors. Overall, performance is acceptable.

A total of $1 6 3 ~ P .$ . aeruginosa isolates were evaluated with ceftazidime-avibactam. The combined results from clinical and challenge isolate testing demonstrated an EA of $8 9 . 6 \%$ and CA of $9 6 . 9 \%$ . There were 4 major errors $( 4 / 1 5 3 = 2 . 6 \% )$ and 1 very major error $\left( 1 / 1 0 \right) =$ $1 0 \%$ ). Due to the lack of an intermediate interpretive criterion, further analysis of the errors was performed and adjustments were made by considering the MIC values of the errors compared to the reference MIC value. Two of the 4 major errors and 1 of the 1 very major errors had an MIC value that was in essential agreement with the reference MIC value.

Therefore, the adjusted major error rate is $1 . 3 \%$ (2/153) and the adjusted very major error rate is $0 \%$ (0/10), which is acceptable.

A limitation statement is included in the device labeling to address the lack of testing with resistant $C .$ . koseri, $K .$ . aerogenes, K. oxytoca, M. morganii, $P .$ . mirabilis, $P .$ . vulgaris and $S .$ . marcescens isolates.

Analysis of trending indicated that MIC values for C. freundii, C. koseri, E. coli, K. aerogenes, K. oxytoca, M. morganii, $P$ . mirabilis, and $P .$ . vulgaris tended to be one doubling dilution higher than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Ceftazidime-avibactam: Citrobacter freundii, Citrobacter koseri, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Morganella morganii, Proteus mirabilis, Proteus vulgaris

Ceftriaxone. A total of 722 Enterobacterales isolates $6 4 ~ C .$ . freundii, $5 4 ~ C .$ . koseri, $8 4 E$ . cloacae, $1 7 5 E$ . coli, $3 5 \ K .$ . aerogenes, $2 9 K .$ . oxytoca, $1 0 9 K$ . pneumoniae, $6 7 P .$ . mirabilis, $1 0 5 \ : S .$ . marcescens) were evaluated with ceftriaxone. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 7 . 5 \%$ and CA of $9 8 . 5 \%$ . There were 3 minor, 4 major and 4 very major errors. When evaluating results by individual species, $E$ . cloacae had 3 very major errors $3 / 3 4 = 8 . 8 \%$ and $S .$ . marcescens had 1 very major error $( 1 / 1 2 = 8 . 3 \% )$ , which are not acceptable. Due to the unacceptable performance for $E .$ . cloacae and $S .$ marcescens, these drug/organism combinations are not indicated for use with the Selux AST System. The following limitation is included in the device labeling to restrict reporting of $E$ . cloacae and $S .$ . marcescens due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

• Ceftriaxone: Enterobacter cloacae, Serratia marcescens

Analysis of trending indicated that MIC values for C. freundii, C. koseri, E. coli, K. aerogenes, K. oxytoca, and $P .$ . mirabilis tended to be one doubling dilution higher than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Ceftriaxone: Citrobacter freundii, Citrobacter koseri, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Proteus mirabilis

Ciprofloxacin. A total of 818 Enterobacterales isolates (62 C. freundii, $5 5 ~ C .$ . koseri, $7 6 E$ . cloacae, $1 7 0 E$ . coli, $3 2 K .$ . aerogenes, $2 9 K .$ . oxytoca, $1 0 5 \ K$ . pneumoniae, $6 3 M .$ morganii, $6 7 P .$ . mirabilis, $5 5 ~ P .$ . vulgaris, 104 S. marcescens) were evaluated with ciprofloxacin. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 6 . 7 \%$ and CA of $9 6 . 2 \%$ . There were 26 minor, 3 major and 2 very major errors. When evaluating results by individual species, S. marcescens had 2 very major errors $( 2 / 1 2 = 1 6 . 7 \%$ ), which is not acceptable. Due to the unacceptable performance for S. marcescens, this drug/organism combination is not indicated for use with the Selux AST System.The following limitation is included in the device labeling to restrict reporting of S. marcescens due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

• Ciprofloxacin: Serratia marcescens

A total of $1 6 9 P$ . aeruginosa isolates were evaluated with ciprofloxacin. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 5 . 9 \%$ and CA of $9 4 . 7 \%$ . There were 5 minor, 4 major and 0 very major errors. Overall, performance is acceptable.

A limitation statement is included in the device labeling to address the lack of testing with resistant $C .$ . koseri and $P .$ . vulgaris isolates.

Analysis of trending indicated that MIC values for $P$ . aeruginosa tended to be one doubling dilution lower than the reference MIC value while MIC values for $C .$ . freundii, C. koseri, E. cloacae, $E$ . coli, $K .$ . aerogenes, $K .$ . oxytoca, M. morganii, and $P$ . vulgaris tended to be one doubling dilution higher than the reference MIC value. The following statements are included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution lower than the reference MIC value:

• Ciprofloxacin: Pseudomonas aeruginosa

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Ciprofloxacin: Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Morganella morganii, Proteus vulgaris

Eravacycline. A total of 487 Enterobacterales isolates $6 2 ~ C .$ . freundii, $7 8 E .$ . cloacae, $1 6 7 E$ . coli, $4 7 K .$ . oxytoca, $1 3 3 K$ . pneumoniae) were evaluated with eravacycline. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 8 . 2 \%$ and CA of $9 8 . 6 \%$ . There were 4 major and 3 very major errors. When evaluating results by individual species, $E .$ . cloacae had 3 major errors $( 3 / 5 9 = 5 . 1 \%$ ), $K .$ . oxytoca had 1 very major error (1/1 $= 1 0 0 \%$ ), and $K .$ . pneumoniae had 2 very major errors $( 2 / 3 0 = 6 . 7 \% )$ ). Due to the lack of an intermediate interpretive criterion (eravacycline only has a “susceptible” category), further analysis of the errors was performed and adjustments were made by considering the MIC values of the errors compared to the reference MIC value. Two of the $3 E .$ . cloacae major errors and 1 of the $1 K .$ . oxytoca very major errors had an MIC value that was in essential agreement with the reference MIC value. Therefore, the adjusted major error rate for $E$ . cloacae is $1 . 7 \%$ (1/59) and the adjusted very major error rate for $K .$ . oxytoca is $0 \% ( 0 / 1 )$ , which is acceptable. None of the $2 K .$ . pneumoniae very major errors were in essential agreement resulting in an unacceptable very major error rate. Due to the unacceptable

performance for $K .$ . pneumoniae, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation is included in the device labeling to restrict reporting of $K .$ . pneumoniae due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

• Eravacycline: Klebsiella pneumoniae

A limitation statement is included in the device labeling to address the lack of testing with resistant $E .$ . coli and K. oxytoca isolates.

Analysis of trending indicated that MIC values for $C .$ . freundii tended to be one doubling dilution higher than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Eravacycline: Citrobacter freundii

Ertapenem. A total of 977 Enterobacterales isolates (56 C. freundii, $7 4 ~ C .$ koseri, $9 5 E .$ . cloacae, $2 1 0 E$ . coli, $5 5 \ K .$ . aerogenes, $2 8 K .$ . oxytoca, $1 4 1 \ K$ . pneumoniae, $6 2 M .$ . morganii, $8 8 ~ P .$ . mirabilis, $1 0 0 P .$ . vulgaris, $6 8 \ : S .$ marcescens) were evaluated with ertapenem. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 4 . 7 \%$ and CA of $9 7 . 4 \%$ . There were 11 minor, 14 major and 0 very major errors. When evaluating results by individual species, $C .$ . freundii had 3 major errors $( 3 / 5 3 = 5 . 7 \% )$ at Selux MIC values of 2, 4 and $8 ~ \mu \mathrm { g / m L }$ which represent $5 . 4 \%$ (3/56) of results from this drug/organism combination. $E .$ . cloacae had an EA of $80 \%$ , a CA of $8 8 . 4 \%$ , and 6 major errors $( 6 / 7 0 =$ $8 . 6 \%$ , which is not acceptable. $K .$ . aerogenes had an EA of $80 \%$ and 2 major errors $( 2 / 5 0 =$ $4 \%$ , which is not acceptable. Due to the unacceptable performance for $E$ . cloacae and $K .$ . aerogenes, these drug/organism combinations are not indicated for use with the Selux AST System. The following limitation is included in the device labeling to address the $C .$ . freundii major errors and restrict reporting of $E$ . cloacae and $K .$ . aerogenes due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Ertapenem: Citrobacter freundii when the Selux MIC is 2, 4 or $8 ~ \mu \mathrm { g / m L }$ due to 3 major errors, Enterobacter cloacae, Klebsiella aerogenes

A limitation statement is included in the device labeling to address the lack of testing with resistant $C .$ . koseri, $K .$ oxytoca, M. morganii, $P .$ . mirabilis, and $P$ . vulgaris isolates.

Analysis of trending indicated that MIC values for $M .$ morganii tended to be one doubling dilution lower than the reference MIC value while MIC values for $C .$ . freundii, C. koseri, $E$ . coli, $P$ . mirabilis, $P .$ . vulgaris and S. marcescens tended to be one doubling dilution higher than the reference MIC value. The following statements are included as footnotes to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution lower than the reference MIC value:

Ertapenem: Morganella morganii

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Ertapenem: Citrobacter freundii, Citrobacter koseri, Escherichia coli, Proteus mirabilis, Proteus vulgaris, Serratia marcescens

Gentamicin. A total of 817 Enterobacterales isolates (indicated species: $5 6 C .$ . freundii, $7 4 ~ C .$ koseri, $9 5 E .$ . cloacae, $2 1 0 E$ . coli, $5 5 \ K .$ . aerogenes, $2 8 K .$ . oxytoca, $1 4 1 \ K$ . pneumoniae, $8 8 ~ P$ . mirabilis, $1 0 0 P .$ . vulgaris, $6 8 \ : S .$ . marcescens; non-indicated species: $6 2 M .$ morganii) were evaluated with gentamicin. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 6 . 0 \%$ and CA of $9 8 . 8 \%$ . There were 7 minor, 1 major and 2 very major errors. When evaluating results by individual species, $M .$ morganii had 1 very major error $( 1 / 8 = 1 2 . 5 \% )$ ) and $P .$ . mirabilis had 1 very major error $( 1 / 6 = 1 6 . 7 \% )$ ), which were considered random errors due to the limited number of resistant isolates tested.

A total of $2 1 8 { \ : } P .$ . aeruginosa were evaluated with gentamicin. The combined results from clinical and challenge isolate testing demonstrated an EA of $8 8 . 5 \%$ and CA of $9 7 . 3 \%$ . There were 6 minor, 0 major and 0 very major errors. Restriction of reporting MIC values of $\leq 0 . 0 6$ $\mu \mathrm { g / m L }$ (lowest reportable MIC value that represents $4 . 1 \%$ (9/218) of results from this drug/organism combination) improved the EA to $9 0 . 4 \%$ , which is acceptable. The following limitation statement is included in the device labeling to restrict reporting of $P .$ . aeruginosa due to the low EA:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combinations:

• Gentamicin: Pseudomonas aeruginosa when the Selux MIC is $\leq 0 . 0 6 ~ \mu \mathrm { g / m L }$

A limitation statement is included in the device labeling to address the lack of testing with resistant $K .$ . aerogenes, M. morganii, $P _ { - }$ . vulgaris, and S. marcescens isolates.

Analysis of trending indicated that MIC values for C. freundii, $E$ . cloacae complex, $E$ . coli, K. oxytoca, and $K .$ . pneumoniae tended to be one doubling dilution lower than the reference MIC value while MIC values for S. marcescens tended to be one doubling dilution higher than the reference MIC value. The following statements are included as footnotes to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution lower than the reference MIC value:

Gentamicin: Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

• Gentamicin: Serratia marcescens

Imipenem. A total of $1 2 6 A$ . baumannii isolates were evaluated with imipenem. The combined results from clinical and challenge isolate testing demonstrated an EA of $8 8 . 9 \%$ and CA of $9 8 . 4 \%$ . There were 0 minor, 0 major and 2 very major errors $( 2 / 6 2 = 3 . 2 \%$ ), which is not acceptable. Due to the unacceptable performance for A. baumannii, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation statement is included in the device labeling to restrict reporting of $A$ . baumannii due to the unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combinations:

Imipenem: Acinetobacter baumannii

Imipenem-relebactam. A total of 471 Enterobacterales isolates (55C. freundii, $5 5 ~ C .$ koseri, $1 7 2 E$ . coli, $3 1 K .$ aerogenes, $2 7 K .$ . oxytoca, $1 3 1 \ K .$ . pneumoniae) were evaluated with imipenem-relebactam. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 3 . 4 \%$ and CA of $9 7 . 5 \%$ . There were 9 minor, 3 major and 0 very major errors. When evaluating results by individual species, $K .$ . oxytoca had 1 major error $( 1 / 2 7 = 3 . 7 \% )$ at a Selux MIC value of $4 ~ \mu \mathrm { g / m L }$ which represents $3 . 7 \%$ (1/27) of results from this drug/organism combination. $K .$ aerogenes and $K .$ . pneumoniae had an EA $- 9 0 \%$ , which is not acceptable. Due to the unacceptable performance for $K .$ . aerogenes and $K .$ . pneumoniae, these drug/organism combinations are not indicated for use with the Selux AST System. The following limitation is included in the device labeling to address the $K .$ . oxytoca major error and restrict reporting of $K .$ . aerogenes and $K .$ . pneumoniae due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Imipenem-relebactam: Klebsiella oxytoca when the Selux MIC is $4 ~ { \mu \mathrm { g / m L } }$ due to one major error, Klebsiella pneumoniae, Klebsiella aerogenes

A total of $1 6 5 ~ P .$ . aeruginosa isolates were evaluated with imipenem-relebactam. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 6 . 4 \%$ and CA of $9 8 . 2 \%$ . There were 3 minor, 0 major and 0 very major errors. Overall, performance was acceptable.

A limitation statement is included in the device labeling to address the lack of testing with resistant $C .$ . koseri, $K .$ . aerogenes, and $K .$ . oxytoca isolates.

Analysis of trending indicated that MIC values for C. freundii tended to be one doubling dilution lower than the reference MIC value while MIC values for $K .$ oxytoca tended to be one doubling dilution higher than the reference MIC value. The following statements are included as footnotes to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution lower than the reference MIC value:

Imipenem-relebactam: Citrobacter freundii

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Imipenem-relebactam: Klebsiella oxytoca

Levofloxacin. A total of 784 Enterobacterales isolates ( $6 3 ~ C .$ freundii, $5 4 ~ C .$ . koseri, $7 5 E$ . cloacae, 171 $E$ . coli, $3 2 K .$ . aerogenes, $2 7 K .$ . oxytoca, $1 1 0 K .$ . pneumoniae, $6 2 M .$ . morganii, $6 7 P .$ . mirabilis, $5 5 P .$ . vulgaris, $6 8 \ : S .$ marcescens) were evaluated with levofloxacin. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 6 . 1 \%$ and CA of $9 4 . 9 \%$ . There were 33 minor, 6 major and 1 very major errors. When evaluating results by individual species, $K .$ . aerogenes had 1 major error $( 1 / 3 0 = 3 . 3 \% )$ at a Selux MIC value of $2 ~ { \mu \mathrm { g / m L } }$ , which represents $3 . 1 \%$ (1/32) of results from this drug/organism combination. C. freundii had 2 major errors $( 2 / 5 5 = 3 . 6 \% )$ ) at a Selux MIC value of $2 ~ { \mu \mathrm { g / m L } }$ which represent $4 . 8 \%$ (3/63) of results from this drug/organism combination, as well as 1 very major error $( 1 / 7 = 1 4 . 3 \% )$ ), which was considered a random error due to the limited number of resistant isolates tested. The following limitation is included in the device labeling to address the major errors:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Levofloxacin: Citrobacter freundii when the Selux MIC is $2 ~ { \mu \mathrm { g / m L } }$ due to two major errors, Klebsiella aerogenes when the Selux MIC is $2 ~ { \mu \mathrm { g / m L } }$ due to one major error

A total of $1 7 1 \ : P .$ . aeruginosa isolates were evaluated with levofloxacin. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 4 . 2 \%$ and CA of $9 0 . 1 \%$ . There were 14 minor, 1 major and 2 very major errors $( 2 / 4 2 = 4 . 8 \%$ ), which is not acceptable. Due to the unacceptable performance for $P$ . aeruginosa, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation is included in the device labeling to restrict reporting of $P .$ . aeruginosa due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

• Levofloxacin: Pseudomonas aeruginosa

A limitation statement is included in the device labeling to address the lack of testing with resistant C. koseri isolates.

Analysis of trending indicated that MIC values for C. freundii, C. koseri, E. cloacae, $E$ . coli, $K$ . aerogenes, K. oxytoca, K. pneumoniae, M. morganii, $P .$ . mirabilis, and $P .$ . vulgaris tended to be one doubling dilution higher than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Levofloxacin: C. freundii, C. koseri, E. cloacae, $E$ . coli, $K .$ . aerogenes, $K .$ . oxytoca, K. pneumoniae, M. morganii, $P .$ . mirabilis, $P .$ . vulgaris

Meropenem. A total of 126 A. baumannii isolates were evaluated with meropenem. The combined results from clinical and challenge isolate testing demonstrated an EA of $8 6 . 5 \%$ and CA of $9 8 . 4 \%$ . There were 0 minor, 2 major $( 2 / 6 3 = 3 . 2 \% )$ and 0 very major errors. Due to the unacceptable performance for A. baumannii, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation statement is included in the device labeling to restrict reporting of $A$ . baumannii due to the unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combinations:

Meropenem: Acinetobacter baumannii

A total of 865 Enterobacterales isolates (indicated species: $7 8 C .$ . freundii, $7 4 ~ C .$ . koseri, $7 4 E$ . cloacae, $1 6 6 E .$ . coli, $2 7 K .$ . oxytoca, $1 2 6 K .$ . pneumoniae, $6 2 M .$ . morganii, $6 6 P$ . mirabilis, 55 $P .$ . vulgaris, $1 0 5 S .$ . marcescens; non-indicated species: $3 2 K .$ . aerogenes) were evaluated with meropenem. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 6 . 3 \%$ and CA of $9 8 . 0 \%$ . There were 4 minor, 12 major and 1 very major errors. When evaluating results by individual species, $C .$ freundii has 3 major errors $( 3 / 7 4 = 4 . 1 \% )$ at Selux MIC values of 16 and $3 2 ~ \mu \mathrm { g / m L }$ , which represent $6 . 4 \%$ (5/78) of results from this drug/organism combination. S. marcescens had 4 major errors $( 4 / 1 0 1 = 4 . 0 \%$ ) at Selux MIC value of 16 and $3 2 ~ \mu \mathrm { g / m L }$ , which represent $6 . 7 \%$ (7/105) of results from this drug/organism combination, as well as 1 very major error $1 / 4 = 2 5 \%$ ) which was considered a random error due to the limited number of resistant isolates tested. The following limitations are included in the device labeling to address the major errors:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Meropenem: Citrobacter freundii complex when the Selux MIC is 16 or 32 $\mu \mathrm { g / m L }$ due to 3 major errors, Serratia marcescens when the Selux MIC is 16 or $3 2 ~ \mu \mathrm { g / m L }$ due to 4 major errors

A total of $1 7 5 { \ : } P .$ . aeruginosa isolates were evaluated with levofloxacin. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 3 . 1 \%$ and CA of $9 6 . 0 \%$ . There were 7 minor, 0 major and 0 very major errors. Overall, performance was acceptable.

A limitation is included in the device labeling to address the lack of testing with resistant $C$ .   
koseri, K. oxytoca, M. morganii, $P .$ . vulgaris isolates.

Analysis of trending indicated that MIC values for $C .$ . freundii, C. koseri, E. cloacae, $K$ . aerogenes, K. oxytoca, K. pneumoniae, $M .$ morganii, $P .$ . mirabilis, $P _ { - }$ . vulgaris, and $S .$ . marcescens tended to be one doubling dilution higher than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Meropenem: Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Serratia marcescens

Meropenem-vaborbactam. A total of 865 Enterobacterales isolates (indicated species: $6 4 ~ C$ freundii, $5 4 ~ C .$ . koseri, $7 0 E .$ . cloacae, $1 6 7 E .$ . coli, $5 0 K .$ aerogenes, $4 7 K .$ . oxytoca, $1 1 3 K$ . pneumoniae, $6 4 M .$ morganii, $6 6 P .$ . mirabilis, $6 5 \ : S .$ marcescens; non-indicated species: 100 $P _ { - }$ . vulgaris) were evaluated with meropenem-vaborbactam. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 1 . 7 \%$ and CA of $9 6 . 9 \%$ . There were 10 minor, 16 major and 1 very major errors. When evaluating results by individual species, $P .$ . mirabilis had an EA of $62 \%$ , CA of $9 7 . 0 \%$ , 2 minor, 0 major and 0 very major errors. $P .$ . vulgaris had an EA of $62 \%$ , CA of $8 1 \%$ , 15 major errors ( $1 5 / 1 0 0 = 1 5 \%$ ). Due to the unacceptable performance for $P _ { - }$ . mirabilis and $P .$ . vulgaris, these drug/organism combinations are not indicated for use with the Selux AST System.The following limitation is included in the device labeling to restrict reporting due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

• Meropenem-vaborbactam: Proteus mirabilis; Proteus vulgaris

A limitation is included in the device labeling to address the lack of testing with resistant $C .$ . koseri, K. aerogenes, K. oxytoca, M. morganii, $P .$ . mirabilis, $P .$ . vulgaris, and S. marcescens isolates.

Analysis of trending indicated that MIC values for $C .$ . freundii, C. koseri, E. cloacae complex, E. coli, K. aerogenes, K. oxytoca, K. pneumoniae, M. morganii, and S. marcescens tended to be one doubling dilution higher than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Meropenem-vaborbactam: Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Serratia marcescens

Minocycline. A total of $1 9 9 A$ . baumannii isolates were evaluated with minocycline. The combined results from clinical and challenge isolate testing demonstrated an EA of $8 8 . 9 \%$ and CA of $9 1 . 0 \%$ . There were 13 minor, 5 major $( 5 / 1 5 0 = 3 . 3 \%$ and 0 very major errors. Due to the unacceptable performance for $A$ . baumannii, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation statement is included in the device labeling to restrict reporting of $A$ . baumannii due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combinations:

Minocycline: Acinetobacter baumannii

A total of 404 Enterobacterales isolates ( $1 9 8 E .$ . coli, $5 3 K .$ aerogenes, $2 7 K .$ . oxytoca, $1 2 6 K .$ . pneumoniae) were evaluated with minocycline. The combined results from clinical and challenge isolate testing demonstrated an EA of $8 9 . 6 \%$ and CA of $9 4 . 3 \%$ . There were 16 minor, 3 major and 4 very major errors. When evaluating results by individual species, $E$ . coli had an EA of $8 7 . 4 \%$ as well as 8 minor, 2 major $( 2 / 1 8 2 = 1 . 1 \% )$ and 1 very major ( $1 / 7 =$

$1 4 . 3 \% )$ errors, which was considered a random error due to the limited number of resistant isolates tested. $K .$ . aerogenes had 1 very major error $1 / 3 = 3 3 . 3 \% )$ ), which was considered a random error due to the limited number of resistant isolates tested. $K .$ . pneumoniae had an EA of $8 8 . 9 \%$ and 2 very major errors $( 2 / 3 3 = 6 . 1 \%$ ) at a Selux MIC of 4. Restricting $K .$ . pneumoniae reporting at a Selux MIC of $4 ~ { \mu \mathrm { g / m L } }$ , which represents $6 . 3 \%$ (8/126) of results from this drug/organism combination addresses both very major errors and improves EA to $8 9 . 8 \%$ . Due to the unacceptable performance for $E .$ . coli, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation statement is included in the device labeling to restrict reporting of $E$ . coli due to unacceptable performance and address the $K .$ . pneumoniae very major errors:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Minocycline: Escherichia coli, Klebsiella pneumoniae when the Selux MIC is 4 $\mu \mathrm { g / m L }$ due to two very major errors

A limitation is included in the device labeling to address the lack of testing with resistant $K .$ .   
oxytoca isolates.

There was no evidence of trending observed with Enterobacterales with minocycline.

Piperacillin-tazobactam. A total of $1 1 3 A .$ . baumannii isolates were evaluated with piperacillin-tazobactam. The combined results from clinical and challenge isolate testing demonstrated an EA of $8 1 . 4 \%$ and CA of $9 1 . 2 \%$ . There were 9 minor errors, 0 major errors and 1 very major error ( $1 / 5 8 = 1 . 7 \%$ . Due to the unacceptable performance for $A$ . baumannii, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation statement is included in the device labeling to restrict reporting of $A$ . baumannii due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combinations:

Piperacillin-tazobactam: Acinetobacter baumannii

A total of 926 Enterobacterales isolates (indicated species: $7 5 ~ C .$ . koseri, $1 7 6 E$ . coli, $1 4 2 K .$ . pneumoniae, $7 5 M .$ morganii, $8 8 ~ P .$ . mirabilis, $5 5 P$ . vulgaris, $6 0 S .$ marcescens; nonindicated species: $7 8 ~ C .$ . freundii, $9 6 E$ . cloacae, $5 3 K .$ . aerogenes, $2 8 K .$ . oxytoca) were evaluated with piperacillin-tazobactam. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 0 . 2 \%$ and CA of $9 4 . 8 \%$ . There were 35 minor, 9 major and 4 very major errors. When evaluating results by individual species, $C .$ . freundii had an EA of $7 9 . 5 \%$ , CA of $8 4 . 6 \%$ as well as 11 minor, 0 major, and 1 very major $( 1 / 1 1 = 9 . 1 \% )$ errors. $E$ . cloacae had an EA and CA of $8 6 . 5 \%$ as well as 9 minor and 4 major $( 4 / 6 1 = 6 . 6 \% )$ errors. $K .$ . aerogenes had an EA of $8 6 . 8 \%$ as well as 2 minor and 2 major $( 2 / 4 2 = 4 . 8 \% )$ errors. S. marcescens had an EA of $6 6 . 7 \%$ as well as 1 minor and 1 very major (1/2) error, which was considered a random error due to the limited number of resistant isolates tested. Due to the unacceptable performance for reporting of $C .$ . freundii, $E .$ . cloacae, $K .$ . aerogenes and S. marcescens, these drug/organism combinations are not indicated for use with the Selux AST System. The following limitation statement is included in the device labeling to restrict reporting of C. freundii, E. cloacae, K. aerogenes and S. marcescens due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

Piperacillin-tazobactam: Citrobacter freundii, Enterobacter cloacae, Klebsiella aerogenes, Serratia marcescens

A total of $2 1 7 P .$ . aeruginosa isolates were evaluated with piperacillin-tazobactam. The combined results from clinical and challenge isolate testing demonstrated an EA of $8 0 . 7 \%$ and CA of $8 3 . 9 \%$ . There were 27 minor errors, 2 major errors $( 2 / 1 6 7 = 1 . 2 \% )$ , and 6 very major errors $( 6 / 2 8 = 2 1 . 4 \%$ ). Due to the unacceptable performance for $P _ { - }$ . aeruginosa, this drug/organism combination is not indicated for use with the Selux AST System. The following limitation statement is included in the device labeling to restrict reporting of $P$ . aeruginosa due to unacceptable performance:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combinations:

Piperacillin-tazobactam: Pseudomonas aeruginosa

A limitation is included in the device labeling to address the lack of testing with resistant $C$ .   
koseri, $P .$ . mirabilis, and $P$ . vulgaris isolates.

Analysis of trending indicated that MIC values for K. oxytoca and $K .$ . pneumoniae tended to be one doubling dilution lower than the reference MIC value while MIC values for $M .$ . morganii, $P .$ . mirabilis and $P .$ . vulgaris tended to be one doubling dilution higher than the reference MIC value. The following statements are included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution lower than the reference MIC value:

Piperacillin-tazobactam: Klebsiella oxytoca, Klebsiella pneumoniae

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:

Piperacillin-tazobactam: Morganella morganii, Proteus mirabilis, Proteus vulgaris

Tobramycin. A total of $1 6 6 P$ . aeruginosa isolates were evaluated with tobramycin. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 3 . 4 \%$ and CA of $9 7 . 6 \%$ . There were 3 minor errors, 1 major error $( 1 / 1 5 0 = 0 . 7 \%$ , and 0 very major errors $( 6 / 2 8 = 2 1 . 4 \%$ ). Overall, performance was acceptable.

There was no evidence of trending observed with $P$ . aeruginosa with tobramycin.

Trimethoprim-Sulfamethoxazole. A total of 526 Enterobacterales isolates (indicated species: $7 6 E$ . cloacae, $2 0 3 \ E$ . coli, $3 2 K .$ . aerogenes, $2 9 K .$ oxytoca, $1 0 9 K .$ pneumoniae; non-indicated species: $7 7 ~ C .$ . freundii) were evaluated with trimethoprim-sulfamethoxazole. The combined results from clinical and challenge isolate testing demonstrated an EA of $9 7 . 0 \%$ and CA of $9 8 . 5 \%$ . There were 0 minor, 2 major and 6 very major errors. When evaluating results by individual species, C. freundii had 1 very major error $( 1 / 1 7 = 5 . 9 \%$ ), $E$ . coli had 4 very major errors $( 4 / 6 7 = 6 . 0 \%$ ), $K .$ . pneumoniae had 2 major $( 2 / 6 1 = 3 . 3 \% )$ and 1 very major $1 / 2 8 = 3 . 6 \%$ errors. Due to the lack of an intermediate interpretive criterion, further analysis of the errors was performed and adjustments were made by considering the MIC values of the errors compared to the reference MIC value. One of the 2 major errors and 1 of the 1 very major errors from $K .$ . pneumoniae had an MIC value that was in essential agreement with the reference MIC value. Therefore, $K .$ . pneumoniae has an adjusted major error rate of $1 . 6 \%$ (1/61) and an adjusted very major error rate of $0 \%$ (0/28), which is acceptable. Due to the unacceptable performance for $C .$ . freundii and $E .$ . coli, these drug/organism combinations are not indicated for use with the Selux AST System. The following limitation statement is included in the device labeling to restrict reporting of $C .$ . freundii and $E$ . coli:

Perform an alternative method of testing prior to reporting results for the following antibiotic/organism combination(s):

• Trimethoprim-Sulfamethoxazole: Citrobacter freundii, Escherichia coli

Analysis of trending indicated that MIC values for $E .$ . cloacae, K. aerogenes, K. oxytoca, and $K .$ . pneumoniae tended to be one doubling dilution higher than the reference MIC value. The following statement is included as a footnote to the AST performance table:

Selux MIC values for the following antimicrobial/organism combinations tended to be one doubling dilution higher than the reference MIC value:   
Trimethoprim-Sulfamethoxazole: Enterobacter cloacae, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae

Table 6. Selux AST System – Gram-Negative Panel Performance   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Tot</td><td colspan="1" rowspan="1">No.EA</td><td colspan="1" rowspan="1">EA%</td><td colspan="1" rowspan="1">EvalEATot</td><td colspan="1" rowspan="1">No.EvalEA</td><td colspan="1" rowspan="1">EvalEA%</td><td colspan="1" rowspan="1">No.CA</td><td colspan="1" rowspan="1">CA%</td><td colspan="1" rowspan="1">No. Ror NS</td><td colspan="1" rowspan="1">No. S</td><td colspan="1" rowspan="1">min</td><td colspan="1" rowspan="1">maj</td><td colspan="1" rowspan="1">vmj</td></tr><tr><td colspan="8" rowspan="1">aAmikacin - Acinetobacter baumannii [Breakpoints (μg/mL): 16 (S), 32 (I), 64 (R)]</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">54.65</td><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">49.35</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">90.7</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">69</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">56</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">31.25</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">54.95</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">46.24</td><td colspan="1" rowspan="1">96</td><td colspan="1" rowspan="1">86.49</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="1" rowspan="1">kpoints</td><td colspan="1" rowspan="1">ug/mL):</td><td colspan="1" rowspan="1">16 (S), 32</td><td colspan="1" rowspan="1">(I), 64 (</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">159</td><td colspan="1" rowspan="1">145</td><td colspan="1" rowspan="1">91.19</td><td colspan="1" rowspan="1">158</td><td colspan="1" rowspan="1">144</td><td colspan="1" rowspan="1">91.14</td><td colspan="1" rowspan="1">156</td><td colspan="1" rowspan="1">98.11</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">154</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">83.33</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">165</td><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">90.91</td><td colspan="1" rowspan="1">163</td><td colspan="1" rowspan="1">148</td><td colspan="1" rowspan="1">90.8</td><td colspan="1" rowspan="1">162</td><td colspan="1" rowspan="1">98.18</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">156</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="3" rowspan="1">Amoxicillin-Clavul</td><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">nterobacterales []</td><td colspan="1" rowspan="1">Breakpoi</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">L): 8 (S),</td><td colspan="1" rowspan="1">16 (I), 3</td><td colspan="1" rowspan="1">2(R))</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">502</td><td colspan="1" rowspan="1">463</td><td colspan="1" rowspan="1">92.23</td><td colspan="1" rowspan="1">454</td><td colspan="1" rowspan="1">415</td><td colspan="1" rowspan="1">91.41</td><td colspan="1" rowspan="1">460</td><td colspan="1" rowspan="1">91.63</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">412</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">98.9</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">97.96</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">98.9</td><td colspan="1" rowspan="1">71</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">593</td><td colspan="1" rowspan="1">553</td><td colspan="1" rowspan="1">93.25</td><td colspan="1" rowspan="1">503</td><td colspan="1" rowspan="1">463</td><td colspan="1" rowspan="1">92.05</td><td colspan="1" rowspan="1">550</td><td colspan="1" rowspan="1">92.75</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">431</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="3" rowspan="1"></td><td colspan="2" rowspan="1">Enterobacterales</td><td colspan="2" rowspan="1">Breakpoints (ug/</td><td colspan="1" rowspan="1">L) 8 (</td><td colspan="1" rowspan="1">), 16 (I).</td><td colspan="1" rowspan="1">32 (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">247</td><td colspan="1" rowspan="1">234</td><td colspan="1" rowspan="1">94.74</td><td colspan="1" rowspan="1">138</td><td colspan="1" rowspan="1">125</td><td colspan="1" rowspan="1">90.58</td><td colspan="1" rowspan="1">244</td><td colspan="1" rowspan="1">98.79</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">135</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">254</td><td colspan="1" rowspan="1">241</td><td colspan="1" rowspan="1">94.88</td><td colspan="1" rowspan="1">138</td><td colspan="1" rowspan="1">125</td><td colspan="1" rowspan="1">90.58</td><td colspan="1" rowspan="1">251</td><td colspan="1" rowspan="1">98.82</td><td colspan="1" rowspan="1">118</td><td colspan="1" rowspan="1">135</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Am</td><td colspan="1" rowspan="1">icillin-S</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">: Acineto</td><td colspan="2" rowspan="1">bacter baumanni</td><td colspan="1" rowspan="1">[Breakr</td><td colspan="1" rowspan="1">oints (ug</td><td colspan="1" rowspan="1">/mL): 8 (</td><td colspan="1" rowspan="1">S). 16 (D)</td><td colspan="1" rowspan="1">32 (R)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">91.74</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">90.99</td><td colspan="1" rowspan="1">112</td><td colspan="1" rowspan="1">92.56</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">65</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">123</td><td colspan="1" rowspan="1">113</td><td colspan="1" rowspan="1">91.87</td><td colspan="1" rowspan="1">113</td><td colspan="1" rowspan="1">103</td><td colspan="1" rowspan="1">91.15</td><td colspan="1" rowspan="1">114</td><td colspan="1" rowspan="1">92.68</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">65</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="9" rowspan="1">Ampicillin-Sulbactam: Enterobacterales [Breakpoints (μg/mL): 8 (S), 16 (I), 32 (R)]</td><td colspan="1" rowspan="1">): 8 (S) 1</td><td colspan="1" rowspan="1">6 (I), 32</td><td colspan="3" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Tot</td><td colspan="1" rowspan="1">No.EA</td><td colspan="1" rowspan="1">EA%</td><td colspan="1" rowspan="1">EvalEATot</td><td colspan="1" rowspan="1">No.EvalEA</td><td colspan="1" rowspan="1">EvalEA%</td><td colspan="1" rowspan="1">No.CA</td><td colspan="1" rowspan="1">CA%</td><td colspan="1" rowspan="1">No. Rr NS</td><td colspan="1" rowspan="1">No. S</td><td colspan="1" rowspan="1">min</td><td colspan="1" rowspan="1">maj</td><td colspan="1" rowspan="1">vmj</td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">518</td><td colspan="1" rowspan="1">502</td><td colspan="1" rowspan="1">96.91</td><td colspan="1" rowspan="1">475</td><td colspan="1" rowspan="1">459</td><td colspan="1" rowspan="1">96.63</td><td colspan="1" rowspan="1">433</td><td colspan="1" rowspan="1">83.59</td><td colspan="1" rowspan="1">163</td><td colspan="1" rowspan="1">279</td><td colspan="1" rowspan="1">81</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">56</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">96.43</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">92.31</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">82.14</td><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">574</td><td colspan="1" rowspan="1">556</td><td colspan="1" rowspan="1">96.86</td><td colspan="1" rowspan="1">501</td><td colspan="1" rowspan="1">483</td><td colspan="1" rowspan="1">96.41</td><td colspan="1" rowspan="1">479</td><td colspan="1" rowspan="1">83.45</td><td colspan="1" rowspan="1">202</td><td colspan="1" rowspan="1">290</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">aA</td><td colspan="1" rowspan="1">ztreonam</td><td colspan="1" rowspan="1">: Enterol</td><td colspan="1" rowspan="1">acterale</td><td colspan="1" rowspan="1">[Break]</td><td colspan="1" rowspan="1">oints (μ</td><td colspan="1" rowspan="1">g/mL): 4</td><td colspan="1" rowspan="1">(S), 8 (I),</td><td colspan="1" rowspan="1">16 (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">159</td><td colspan="1" rowspan="1">156</td><td colspan="1" rowspan="1">98.11</td><td colspan="1" rowspan="1">144</td><td colspan="1" rowspan="1">141</td><td colspan="1" rowspan="1">97.92</td><td colspan="1" rowspan="1">154</td><td colspan="1" rowspan="1">96.86</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">129</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">95.83</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">183</td><td colspan="1" rowspan="1">179</td><td colspan="1" rowspan="1">97.81</td><td colspan="1" rowspan="1">154</td><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">97.4</td><td colspan="1" rowspan="1">178</td><td colspan="1" rowspan="1">97.27</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">129</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Aztreor</td><td colspan="1" rowspan="1">am: Pse</td><td colspan="1" rowspan="1">domona</td><td colspan="1" rowspan="1">s aerugi</td><td colspan="1" rowspan="1">osa [Br</td><td colspan="1" rowspan="1">akpoints</td><td colspan="1" rowspan="1">(μg/mL</td><td colspan="1" rowspan="1">: 8 (S), 1</td><td colspan="1" rowspan="1"> (I), 32</td><td colspan="1" rowspan="1">R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">208</td><td colspan="1" rowspan="1">189</td><td colspan="1" rowspan="1">90.87</td><td colspan="1" rowspan="1">202</td><td colspan="1" rowspan="1">183</td><td colspan="1" rowspan="1">90.59</td><td colspan="1" rowspan="1">181</td><td colspan="1" rowspan="1">87.02</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">158</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">219</td><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">91.32</td><td colspan="1" rowspan="1">206</td><td colspan="1" rowspan="1">187</td><td colspan="1" rowspan="1">90.78</td><td colspan="1" rowspan="1">192</td><td colspan="1" rowspan="1">87.67</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">158</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">efazolin</td><td colspan="1" rowspan="1">Enterob</td><td colspan="1" rowspan="1">acterales</td><td colspan="1" rowspan="1">[Breakp</td><td colspan="1" rowspan="1">oints (μg</td><td colspan="1" rowspan="1">/mL): 1</td><td colspan="1" rowspan="1">S), 2 (I),</td><td colspan="1" rowspan="1">4 (R)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">368</td><td colspan="1" rowspan="1">344</td><td colspan="1" rowspan="1">93.48</td><td colspan="1" rowspan="1">290</td><td colspan="1" rowspan="1">266</td><td colspan="1" rowspan="1">91.72</td><td colspan="1" rowspan="1">264</td><td colspan="1" rowspan="1">71.74</td><td colspan="1" rowspan="1">174</td><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">412</td><td colspan="1" rowspan="1">388</td><td colspan="1" rowspan="1">94.17</td><td colspan="1" rowspan="1">290</td><td colspan="1" rowspan="1">266</td><td colspan="1" rowspan="1">91.72</td><td colspan="1" rowspan="1">308</td><td colspan="1" rowspan="1">74.76</td><td colspan="1" rowspan="1">218</td><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Ce</td><td colspan="1" rowspan="1">fepime:]</td><td colspan="1" rowspan="1">Enteroba</td><td colspan="1" rowspan="1">cterales [</td><td colspan="1" rowspan="1">Breakpo</td><td colspan="1" rowspan="1">nts (μg/</td><td colspan="1" rowspan="1">nL):2 (s</td><td colspan="1" rowspan="1">), 4-8 (I),</td><td colspan="1" rowspan="1">16 (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">905</td><td colspan="1" rowspan="1">857</td><td colspan="1" rowspan="1">94.7</td><td colspan="1" rowspan="1">127</td><td colspan="1" rowspan="1">79</td><td colspan="1" rowspan="1">62.2</td><td colspan="1" rowspan="1">867</td><td colspan="1" rowspan="1">95.8</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">810</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">96.08</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">88.24</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">956</td><td colspan="1" rowspan="1">906</td><td colspan="1" rowspan="1">94.77</td><td colspan="1" rowspan="1">144</td><td colspan="1" rowspan="1">94</td><td colspan="1" rowspan="1">65.28</td><td colspan="1" rowspan="1">918</td><td colspan="1" rowspan="1">96.03</td><td colspan="1" rowspan="1">127</td><td colspan="1" rowspan="1">812</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">aCefep</td><td colspan="1" rowspan="1">ime: Pse</td><td colspan="1" rowspan="1">udomon</td><td colspan="1" rowspan="1">is aerugi</td><td colspan="1" rowspan="1">nosa [Br</td><td colspan="1" rowspan="1">eakpoint</td><td colspan="1" rowspan="1">(μg/mI</td><td colspan="1" rowspan="1">): 8 (S),-</td><td colspan="1" rowspan="1">(I), 16 (I</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">208</td><td colspan="1" rowspan="1">182</td><td colspan="1" rowspan="1">87.5</td><td colspan="1" rowspan="1">203</td><td colspan="1" rowspan="1">177</td><td colspan="1" rowspan="1">87.19</td><td colspan="1" rowspan="1">188</td><td colspan="1" rowspan="1">90.38</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">178</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">85.71</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">215</td><td colspan="1" rowspan="1">188</td><td colspan="1" rowspan="1">87.44</td><td colspan="1" rowspan="1">205</td><td colspan="1" rowspan="1">178</td><td colspan="1" rowspan="1">86.83</td><td colspan="1" rowspan="1">195</td><td colspan="1" rowspan="1">90.7</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">178</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">efoxitin:</td><td colspan="1" rowspan="1">Enterob:</td><td colspan="1" rowspan="1">cterales</td><td colspan="1" rowspan="1">[Breakp</td><td colspan="1" rowspan="1">ints (μg</td><td colspan="1" rowspan="1">mL): 4 (</td><td colspan="1" rowspan="1">S), 8(I)</td><td colspan="1" rowspan="1">6 (R))</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">600</td><td colspan="1" rowspan="1">551</td><td colspan="1" rowspan="1">91.83</td><td colspan="1" rowspan="1">576</td><td colspan="1" rowspan="1">527</td><td colspan="1" rowspan="1">91.49</td><td colspan="1" rowspan="1">474</td><td colspan="1" rowspan="1">79</td><td colspan="1" rowspan="1">71</td><td colspan="1" rowspan="1">394</td><td colspan="1" rowspan="1">114</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">637</td><td colspan="1" rowspan="1">588</td><td colspan="1" rowspan="1">92.31</td><td colspan="1" rowspan="1">591</td><td colspan="1" rowspan="1">542</td><td colspan="1" rowspan="1">91.71</td><td colspan="1" rowspan="1">511</td><td colspan="1" rowspan="1">80.22</td><td colspan="1" rowspan="1">106</td><td colspan="1" rowspan="1">396</td><td colspan="1" rowspan="1">114</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">aCeftazi</td><td colspan="1" rowspan="1">lime: Ac</td><td colspan="1" rowspan="1">netobac</td><td colspan="1" rowspan="1">er baum</td><td colspan="1" rowspan="1">annii [B</td><td colspan="1" rowspan="1">eakpoint</td><td colspan="1" rowspan="1">s (μg/mI</td><td colspan="1" rowspan="1">): 8 (S), 1</td><td colspan="1" rowspan="1">6 (I), 32</td><td colspan="1" rowspan="1">(R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">105</td><td colspan="1" rowspan="1">86.78</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">74</td><td colspan="1" rowspan="1">82.22</td><td colspan="1" rowspan="1">114</td><td colspan="1" rowspan="1">94.21</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">83.33</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">127</td><td colspan="1" rowspan="1">110</td><td colspan="1" rowspan="1">86.61</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">81.52</td><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">94.49</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Ce</td><td colspan="1" rowspan="1">tazidime</td><td colspan="1" rowspan="1">: Enterol</td><td colspan="1" rowspan="1">oacterale</td><td colspan="1" rowspan="1">; [Break</td><td colspan="1" rowspan="1">boints (μ</td><td colspan="1" rowspan="1">g/mL): 4</td><td colspan="1" rowspan="1">(S), 8 (I),</td><td colspan="1" rowspan="1">16 (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">670</td><td colspan="1" rowspan="1">635</td><td colspan="1" rowspan="1">94.78</td><td colspan="1" rowspan="1">140</td><td colspan="1" rowspan="1">105</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">642</td><td colspan="1" rowspan="1">95.82</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">563</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">117</td><td colspan="1" rowspan="1">117</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">117</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">113</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">787</td><td colspan="1" rowspan="1">752</td><td colspan="1" rowspan="1">95.55</td><td colspan="1" rowspan="1">151</td><td colspan="1" rowspan="1">116</td><td colspan="1" rowspan="1">76.82</td><td colspan="1" rowspan="1">759</td><td colspan="1" rowspan="1">96.44</td><td colspan="1" rowspan="1">208</td><td colspan="1" rowspan="1">567</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">aCeftazi</td><td colspan="1" rowspan="1">dime: Ps</td><td colspan="1" rowspan="1">eudomor</td><td colspan="1" rowspan="1">as aerug</td><td colspan="1" rowspan="1">inosa [E</td><td colspan="1" rowspan="1">reakpoir</td><td colspan="1" rowspan="1">ts (μg/m</td><td colspan="1" rowspan="1">L): 8 (S),</td><td colspan="1" rowspan="1">- (I),16</td><td colspan="1" rowspan="1">R )]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">211</td><td colspan="1" rowspan="1">185</td><td colspan="1" rowspan="1">87.68</td><td colspan="1" rowspan="1">205</td><td colspan="1" rowspan="1">179</td><td colspan="1" rowspan="1">87.32</td><td colspan="1" rowspan="1">196</td><td colspan="1" rowspan="1">92.89</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">177</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">92.31</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">87.5</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">224</td><td colspan="1" rowspan="1">197</td><td colspan="1" rowspan="1">87.95</td><td colspan="1" rowspan="1">213</td><td colspan="1" rowspan="1">186</td><td colspan="1" rowspan="1">87.32</td><td colspan="1" rowspan="1">209</td><td colspan="1" rowspan="1">93.3</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">178</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Ceftazid</td><td colspan="1" rowspan="1">ime-avib</td><td colspan="1" rowspan="1">actam: </td><td colspan="1" rowspan="1">nterobac</td><td colspan="1" rowspan="1">terales []</td><td colspan="1" rowspan="1">Breakpoi</td><td colspan="1" rowspan="1">hts (μg/n</td><td colspan="1" rowspan="1">L): 8 (S)</td><td colspan="1" rowspan="1">- (I), 16</td><td colspan="1" rowspan="1">(R)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">772</td><td colspan="1" rowspan="1">751</td><td colspan="1" rowspan="1">97.28</td><td colspan="1" rowspan="1">211</td><td colspan="1" rowspan="1">190</td><td colspan="1" rowspan="1">90.05</td><td colspan="1" rowspan="1">767</td><td colspan="1" rowspan="1">99.35</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">770</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">97.67</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">90.91</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">815</td><td colspan="1" rowspan="1">793</td><td colspan="1" rowspan="1">97.3</td><td colspan="1" rowspan="1">222</td><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">90.09</td><td colspan="1" rowspan="1">810</td><td colspan="1" rowspan="1">99.39</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">783</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Cef</td><td colspan="1" rowspan="1">azidime-</td><td colspan="1" rowspan="1">avibacta</td><td colspan="1" rowspan="1">n: Psua</td><td colspan="1" rowspan="1">omonas</td><td colspan="1" rowspan="1">aerugind</td><td colspan="1" rowspan="1">sa [Brea</td><td colspan="1" rowspan="1">xpoints (</td><td colspan="1" rowspan="1">g/mL)</td><td colspan="1" rowspan="1">(S), - (I</td><td colspan="1" rowspan="1">, 16 (R</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">157</td><td colspan="1" rowspan="1">140</td><td colspan="1" rowspan="1">89.17</td><td colspan="1" rowspan="1">153</td><td colspan="1" rowspan="1">136</td><td colspan="1" rowspan="1">88.89</td><td colspan="1" rowspan="1">153</td><td colspan="1" rowspan="1">97.45</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">152</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">83.33</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">163</td><td colspan="1" rowspan="1">146</td><td colspan="1" rowspan="1">89.57</td><td colspan="1" rowspan="1">155</td><td colspan="1" rowspan="1">138</td><td colspan="1" rowspan="1">89.03</td><td colspan="1" rowspan="1">158</td><td colspan="1" rowspan="1">96.93</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">153</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">C</td><td colspan="1" rowspan="1">ftriaxon</td><td colspan="1" rowspan="1">e: Entero</td><td colspan="1" rowspan="1">bacterale</td><td colspan="1" rowspan="1">s [Break</td><td colspan="1" rowspan="1">points (μµ</td><td colspan="1" rowspan="1">g/mL): 1</td><td colspan="1" rowspan="1">(S), 2 (I)</td><td colspan="1" rowspan="1">4 (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">666</td><td colspan="1" rowspan="1">648</td><td colspan="1" rowspan="1">97.3</td><td colspan="1" rowspan="1">68</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">73.53</td><td colspan="1" rowspan="1">655</td><td colspan="1" rowspan="1">98.35</td><td colspan="1" rowspan="1">134</td><td colspan="1" rowspan="1">530</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">56</td><td colspan="1" rowspan="1">56</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">56</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">722</td><td colspan="1" rowspan="1">704</td><td colspan="1" rowspan="1">97.51</td><td colspan="1" rowspan="1">69</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">73.91</td><td colspan="1" rowspan="1">711</td><td colspan="1" rowspan="1">98.48</td><td colspan="1" rowspan="1">188</td><td colspan="1" rowspan="1">531</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Cipro</td><td colspan="1" rowspan="1">loxacin:</td><td colspan="1" rowspan="1">Enterob</td><td colspan="1" rowspan="1">acterales</td><td colspan="1" rowspan="1">[Breakp</td><td colspan="1" rowspan="1">oints (μg</td><td colspan="1" rowspan="1">mL): 0.</td><td colspan="1" rowspan="1">5 (S), 0.5</td><td colspan="1" rowspan="1">(I), 1 (R</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">770</td><td colspan="1" rowspan="1">743</td><td colspan="1" rowspan="1">96.49</td><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">123</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">739</td><td colspan="1" rowspan="1">95.97</td><td colspan="1" rowspan="1">130</td><td colspan="1" rowspan="1">622</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Tot</td><td colspan="1" rowspan="1">No.EA</td><td colspan="1" rowspan="1">EA%</td><td colspan="1" rowspan="1">EAEvalTot</td><td colspan="1" rowspan="1">EvalEA</td><td colspan="1" rowspan="1">EA%</td><td colspan="1" rowspan="1">No.CA</td><td colspan="1" rowspan="1">CA%</td><td colspan="1" rowspan="1">No. Rr NS</td><td colspan="1" rowspan="1">No. S</td><td colspan="1" rowspan="1">min</td><td colspan="1" rowspan="1">maj</td><td colspan="1" rowspan="1">vmj</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">818</td><td colspan="1" rowspan="1">791</td><td colspan="1" rowspan="1">96.7</td><td colspan="1" rowspan="1">156</td><td colspan="1" rowspan="1">129</td><td colspan="1" rowspan="1">82.69</td><td colspan="1" rowspan="1">787</td><td colspan="1" rowspan="1">96.21</td><td colspan="1" rowspan="1">177</td><td colspan="1" rowspan="1">623</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Ciproflox</td><td colspan="1" rowspan="1">acin: Ps</td><td colspan="1" rowspan="1">eudomor</td><td colspan="1" rowspan="1">as aerug</td><td colspan="1" rowspan="1">inosa [B</td><td colspan="1" rowspan="1">reakpoin</td><td colspan="1" rowspan="1">ts (μg/m</td><td colspan="1" rowspan="1">): 0.5 (S</td><td colspan="1" rowspan="1">, 1 (I), 2</td><td colspan="1" rowspan="1">(R)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">159</td><td colspan="1" rowspan="1">152</td><td colspan="1" rowspan="1">95.6</td><td colspan="1" rowspan="1">147</td><td colspan="1" rowspan="1">140</td><td colspan="1" rowspan="1">95.24</td><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">94.34</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">132</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">169</td><td colspan="1" rowspan="1">162</td><td colspan="1" rowspan="1">95.86</td><td colspan="1" rowspan="1">148</td><td colspan="1" rowspan="1">141</td><td colspan="1" rowspan="1">95.27</td><td colspan="1" rowspan="1">160</td><td colspan="1" rowspan="1">94.67</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">132</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Era</td><td colspan="1" rowspan="1">vacyclin</td><td colspan="1" rowspan="1">: Entero</td><td colspan="1" rowspan="1">bacterale</td><td colspan="1" rowspan="1">s [Break</td><td colspan="1" rowspan="1">points (µ</td><td colspan="1" rowspan="1">g/mL): 0</td><td colspan="1" rowspan="1">.5 (S), - (</td><td colspan="1" rowspan="1">), - (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">441</td><td colspan="1" rowspan="1">432</td><td colspan="1" rowspan="1">97.96</td><td colspan="1" rowspan="1">436</td><td colspan="1" rowspan="1">427</td><td colspan="1" rowspan="1">97.94</td><td colspan="1" rowspan="1">434</td><td colspan="1" rowspan="1">98.41</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">418</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">487</td><td colspan="1" rowspan="1">478</td><td colspan="1" rowspan="1">98.15</td><td colspan="1" rowspan="1">475</td><td colspan="1" rowspan="1">466</td><td colspan="1" rowspan="1">98.11</td><td colspan="1" rowspan="1">480</td><td colspan="1" rowspan="1">98.56</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">433</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Er</td><td colspan="1" rowspan="1">apenem:</td><td colspan="1" rowspan="1">Enterob</td><td colspan="1" rowspan="1">acterales</td><td colspan="1" rowspan="1">[Breakp</td><td colspan="1" rowspan="1">oints (μg</td><td colspan="1" rowspan="1">mL): 0.5</td><td colspan="1" rowspan="1">(S), 1 (I)</td><td colspan="1" rowspan="1">, 2 (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">880</td><td colspan="1" rowspan="1">832</td><td colspan="1" rowspan="1">94.55</td><td colspan="1" rowspan="1">123</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">60.98</td><td colspan="1" rowspan="1">857</td><td colspan="1" rowspan="1">97.39</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">842</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">95.88</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">71.43</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">97.94</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">977</td><td colspan="1" rowspan="1">925</td><td colspan="1" rowspan="1">94.68</td><td colspan="1" rowspan="1">137</td><td colspan="1" rowspan="1">85</td><td colspan="1" rowspan="1">62.04</td><td colspan="1" rowspan="1">952</td><td colspan="1" rowspan="1">97.44</td><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">849</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Ge</td><td colspan="1" rowspan="1">ntamicin</td><td colspan="1" rowspan="1">Enterob</td><td colspan="1" rowspan="1">acterales</td><td colspan="1" rowspan="1">[Breakp</td><td colspan="1" rowspan="1">oints (μg</td><td colspan="1" rowspan="1">/mL): 4</td><td colspan="1" rowspan="1">(S), 8 (I),</td><td colspan="1" rowspan="1">16 (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">745</td><td colspan="1" rowspan="1">713</td><td colspan="1" rowspan="1">95.7</td><td colspan="1" rowspan="1">704</td><td colspan="1" rowspan="1">672</td><td colspan="1" rowspan="1">95.45</td><td colspan="1" rowspan="1">735</td><td colspan="1" rowspan="1">98.66</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">679</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">71</td><td colspan="1" rowspan="1">98.61</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">817</td><td colspan="1" rowspan="1">784</td><td colspan="1" rowspan="1">95.96</td><td colspan="1" rowspan="1">724</td><td colspan="1" rowspan="1">691</td><td colspan="1" rowspan="1">95.44</td><td colspan="1" rowspan="1">807</td><td colspan="1" rowspan="1">98.78</td><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">690</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Gentam</td><td colspan="1" rowspan="1">icin: Pse</td><td colspan="1" rowspan="1">udomon</td><td colspan="1" rowspan="1">s aerug</td><td colspan="1" rowspan="1">nosa [B</td><td colspan="1" rowspan="1">eakpoint</td><td colspan="1" rowspan="1">s (μg/mI</td><td colspan="1" rowspan="1">): 4 (S), 8</td><td colspan="1" rowspan="1">(I), 16 (</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">208</td><td colspan="1" rowspan="1">183</td><td colspan="1" rowspan="1">87.98</td><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">175</td><td colspan="1" rowspan="1">87.5</td><td colspan="1" rowspan="1">202</td><td colspan="1" rowspan="1">97.12</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">195</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">218</td><td colspan="1" rowspan="1">193</td><td colspan="1" rowspan="1">88.53</td><td colspan="1" rowspan="1">202</td><td colspan="1" rowspan="1">177</td><td colspan="1" rowspan="1">87.62</td><td colspan="1" rowspan="1">212</td><td colspan="1" rowspan="1">97.25</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">197</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">nem: Ac</td><td colspan="1" rowspan="1">netobac</td><td colspan="1" rowspan="1">er baum</td><td colspan="1" rowspan="1">an [B</td><td colspan="1" rowspan="1">eakpoint</td><td colspan="1" rowspan="1">s (μg/mI</td><td colspan="1" rowspan="1">): 2 (S), 4</td><td colspan="1" rowspan="1">(I), 8 (R</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">107</td><td colspan="1" rowspan="1">88.43</td><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">63</td><td colspan="1" rowspan="1">81.82</td><td colspan="1" rowspan="1">119</td><td colspan="1" rowspan="1">98.35</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">126</td><td colspan="1" rowspan="1">112</td><td colspan="1" rowspan="1">88.89</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">82.05</td><td colspan="1" rowspan="1">124</td><td colspan="1" rowspan="1">98.41</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Imipene</td><td colspan="1" rowspan="1">m-Releb</td><td colspan="1" rowspan="1">actam: </td><td colspan="1" rowspan="1">nterobac</td><td colspan="1" rowspan="1">terales []</td><td colspan="1" rowspan="1">Breakpoi</td><td colspan="1" rowspan="1">hts (μg/n</td><td colspan="1" rowspan="1">L): 1 (S)</td><td colspan="1" rowspan="1">2 (I), 4 (</td><td colspan="1" rowspan="1">R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">433</td><td colspan="1" rowspan="1">406</td><td colspan="1" rowspan="1">93.76</td><td colspan="1" rowspan="1">427</td><td colspan="1" rowspan="1">400</td><td colspan="1" rowspan="1">93.68</td><td colspan="1" rowspan="1">422</td><td colspan="1" rowspan="1">97.46</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">428</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">89.47</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">89.19</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">97.37</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">471</td><td colspan="1" rowspan="1">440</td><td colspan="1" rowspan="1">93.42</td><td colspan="1" rowspan="1">464</td><td colspan="1" rowspan="1">433</td><td colspan="1" rowspan="1">93.32</td><td colspan="1" rowspan="1">459</td><td colspan="1" rowspan="1">97.45</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">436</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">penem-R</td><td colspan="1" rowspan="1">elebacta</td><td colspan="1" rowspan="1">n: Pseua</td><td colspan="1" rowspan="1">omonas</td><td colspan="1" rowspan="1">aerugind</td><td colspan="1" rowspan="1">sa [Brea</td><td colspan="1" rowspan="1">xpoints (</td><td colspan="1" rowspan="1">ug/mL):2</td><td colspan="1" rowspan="1">(S), 4 (I</td><td colspan="1" rowspan="1">), 8 (R)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">158</td><td colspan="1" rowspan="1">152</td><td colspan="1" rowspan="1">96.2</td><td colspan="1" rowspan="1">158</td><td colspan="1" rowspan="1">152</td><td colspan="1" rowspan="1">96.2</td><td colspan="1" rowspan="1">155</td><td colspan="1" rowspan="1">98.1</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">153</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">165</td><td colspan="1" rowspan="1">159</td><td colspan="1" rowspan="1">96.36</td><td colspan="1" rowspan="1">162</td><td colspan="1" rowspan="1">156</td><td colspan="1" rowspan="1">96.3</td><td colspan="1" rowspan="1">162</td><td colspan="1" rowspan="1">98.18</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">157</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Lev</td><td colspan="1" rowspan="1">ofloxacir</td><td colspan="1" rowspan="1">: Entero</td><td colspan="1" rowspan="1">oacterale</td><td colspan="1" rowspan="1">; [Break</td><td colspan="1" rowspan="1">ooints (μ</td><td colspan="1" rowspan="1">g/mL): 0</td><td colspan="1" rowspan="1">5 (S), 1 (</td><td colspan="1" rowspan="1">), 2 (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">732</td><td colspan="1" rowspan="1">701</td><td colspan="1" rowspan="1">95.77</td><td colspan="1" rowspan="1">235</td><td colspan="1" rowspan="1">204</td><td colspan="1" rowspan="1">86.81</td><td colspan="1" rowspan="1">692</td><td colspan="1" rowspan="1">94.54</td><td colspan="1" rowspan="1">112</td><td colspan="1" rowspan="1">600</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">784</td><td colspan="1" rowspan="1">753</td><td colspan="1" rowspan="1">96.05</td><td colspan="1" rowspan="1">242</td><td colspan="1" rowspan="1">211</td><td colspan="1" rowspan="1">87.19</td><td colspan="1" rowspan="1">744</td><td colspan="1" rowspan="1">94.9</td><td colspan="1" rowspan="1">161</td><td colspan="1" rowspan="1">603</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">aLevoflo</td><td colspan="1" rowspan="1">xacin: P</td><td colspan="1" rowspan="1">seudomo</td><td colspan="1" rowspan="1">nas aeru</td><td colspan="1" rowspan="1">ginosa [</td><td colspan="1" rowspan="1">Breakpoi</td><td colspan="1" rowspan="1">hts (μg/n</td><td colspan="1" rowspan="1">L): 1 (S)</td><td colspan="1" rowspan="1">2 (I), 4</td><td colspan="1" rowspan="1">R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">159</td><td colspan="1" rowspan="1">149</td><td colspan="1" rowspan="1">93.71</td><td colspan="1" rowspan="1">148</td><td colspan="1" rowspan="1">138</td><td colspan="1" rowspan="1">93.24</td><td colspan="1" rowspan="1">142</td><td colspan="1" rowspan="1">89.31</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">117</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">171</td><td colspan="1" rowspan="1">161</td><td colspan="1" rowspan="1">94.15</td><td colspan="1" rowspan="1">151</td><td colspan="1" rowspan="1">141</td><td colspan="1" rowspan="1">93.38</td><td colspan="1" rowspan="1">154</td><td colspan="1" rowspan="1">90.06</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">117</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">aMerop</td><td colspan="1" rowspan="1">enem: A</td><td colspan="1" rowspan="1">cinetoba</td><td colspan="1" rowspan="1">cter baur</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">reakpoin</td><td colspan="1" rowspan="1">ts (μg/m</td><td colspan="1" rowspan="1">−): 2 (S),</td><td colspan="1" rowspan="1">4 (I), 8 (]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">121</td><td colspan="1" rowspan="1">104</td><td colspan="1" rowspan="1">85.95</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">59.52</td><td colspan="1" rowspan="1">119</td><td colspan="1" rowspan="1">98.35</td><td colspan="1" rowspan="1">58</td><td colspan="1" rowspan="1">63</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">126</td><td colspan="1" rowspan="1">109</td><td colspan="1" rowspan="1">86.51</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">59.52</td><td colspan="1" rowspan="1">124</td><td colspan="1" rowspan="1">98.41</td><td colspan="1" rowspan="1">63</td><td colspan="1" rowspan="1">63</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">M</td><td colspan="1" rowspan="1">cropenen</td><td colspan="1" rowspan="1">: Entero</td><td colspan="1" rowspan="1">bacterale</td><td colspan="1" rowspan="1">s [Break</td><td colspan="1" rowspan="1">points (µ</td><td colspan="1" rowspan="1">g/mL): 1</td><td colspan="1" rowspan="1">(S), 2 (I)</td><td colspan="1" rowspan="1">4 (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">805</td><td colspan="1" rowspan="1">776</td><td colspan="1" rowspan="1">96.4</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">46.3</td><td colspan="1" rowspan="1">789</td><td colspan="1" rowspan="1">98.01</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">777</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">95</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">59</td><td colspan="1" rowspan="1">98.33</td><td colspan="1" rowspan="1">59</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">865</td><td colspan="1" rowspan="1">833</td><td colspan="1" rowspan="1">96.3</td><td colspan="1" rowspan="1">79</td><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">59.49</td><td colspan="1" rowspan="1">848</td><td colspan="1" rowspan="1">98.03</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">778</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Merop</td><td colspan="1" rowspan="1">nem: Ps</td><td colspan="1" rowspan="1">eudomor</td><td colspan="1" rowspan="1">as aerug</td><td colspan="1" rowspan="1">inosa [B</td><td colspan="1" rowspan="1">reakpoin</td><td colspan="1" rowspan="1">ts (μg/m</td><td colspan="1" rowspan="1">): 2 (S),</td><td colspan="1" rowspan="1">4 (I), 8 (]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">159</td><td colspan="1" rowspan="1">148</td><td colspan="1" rowspan="1">93.08</td><td colspan="1" rowspan="1">131</td><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">91.6</td><td colspan="1" rowspan="1">152</td><td colspan="1" rowspan="1">95.6</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">131</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">93.75</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">90.91</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Tot</td><td colspan="1" rowspan="1">No.EA</td><td colspan="1" rowspan="1">EA%</td><td colspan="1" rowspan="1">EvalEATot</td><td colspan="1" rowspan="1">No.EvalEA</td><td colspan="1" rowspan="1">EvalEA%</td><td colspan="1" rowspan="1">No.CA</td><td colspan="1" rowspan="1">CA%</td><td colspan="1" rowspan="1">No. Ror NS</td><td colspan="1" rowspan="1">No. S</td><td colspan="1" rowspan="1">min</td><td colspan="1" rowspan="1">maj</td><td colspan="1" rowspan="1">vmj</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">175</td><td colspan="1" rowspan="1">163</td><td colspan="1" rowspan="1">93.14</td><td colspan="1" rowspan="1">142</td><td colspan="1" rowspan="1">130</td><td colspan="1" rowspan="1">91.55</td><td colspan="1" rowspan="1">168</td><td colspan="1" rowspan="1">96</td><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">132</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="3" rowspan="1">Breakpoints (μg/mL): 4 (S)</td><td colspan="4" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">817</td><td colspan="1" rowspan="1">748</td><td colspan="1" rowspan="1">91.55</td><td colspan="1" rowspan="1">152</td><td colspan="1" rowspan="1">83</td><td colspan="1" rowspan="1">54.61</td><td colspan="1" rowspan="1">791</td><td colspan="1" rowspan="1">96.82</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">810</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">95.35</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">83.33</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">97.67</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">860</td><td colspan="1" rowspan="1">789</td><td colspan="1" rowspan="1">91.74</td><td colspan="1" rowspan="1">164</td><td colspan="1" rowspan="1">93</td><td colspan="1" rowspan="1">56.71</td><td colspan="1" rowspan="1">833</td><td colspan="1" rowspan="1">96.86</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">816</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="5" rowspan="1">aMinocycline: Acinetobacter baumannii [B</td><td colspan="1" rowspan="1">reakpoin</td><td colspan="1" rowspan="1">s (μg/mI</td><td colspan="1" rowspan="1">): 4 (S), 9</td><td colspan="1" rowspan="1">(I), 16 (</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">196</td><td colspan="1" rowspan="1">174</td><td colspan="1" rowspan="1">88.78</td><td colspan="1" rowspan="1">96</td><td colspan="1" rowspan="1">74</td><td colspan="1" rowspan="1">77.08</td><td colspan="1" rowspan="1">178</td><td colspan="1" rowspan="1">90.82</td><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">148</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">199</td><td colspan="1" rowspan="1">177</td><td colspan="1" rowspan="1">88.94</td><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">77.78</td><td colspan="1" rowspan="1">181</td><td colspan="1" rowspan="1">90.95</td><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="3" rowspan="1">Minocycline: Enterol</td><td colspan="4" rowspan="1">acterales [Breakpoints (μg/mL): 4</td><td colspan="1" rowspan="1">(S), 8 (I),</td><td colspan="2" rowspan="1">1 6 (R ))</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">381</td><td colspan="1" rowspan="1">341</td><td colspan="1" rowspan="1">89.5</td><td colspan="1" rowspan="1">339</td><td colspan="1" rowspan="1">299</td><td colspan="1" rowspan="1">88.2</td><td colspan="1" rowspan="1">358</td><td colspan="1" rowspan="1">93.96</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">334</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">91.3</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">86.67</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">404</td><td colspan="1" rowspan="1">362</td><td colspan="1" rowspan="1">89.6</td><td colspan="1" rowspan="1">354</td><td colspan="1" rowspan="1">312</td><td colspan="1" rowspan="1">88.14</td><td colspan="1" rowspan="1">381</td><td colspan="1" rowspan="1">94.31</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">343</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">aPiperac</td><td colspan="1" rowspan="1">llin-Tazo</td><td colspan="1" rowspan="1">bactam:</td><td colspan="1" rowspan="1">Acinetol</td><td colspan="2" rowspan="1">acter baumannii</td><td colspan="1" rowspan="1">Breakp</td><td colspan="1" rowspan="1">ints (μg/</td><td colspan="1" rowspan="1">L): 16(s</td><td colspan="1" rowspan="1">), 32-64</td><td colspan="1" rowspan="1">(I), 128</td><td colspan="1" rowspan="1">(R))</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">108</td><td colspan="1" rowspan="1">87</td><td colspan="1" rowspan="1">80.56</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">32.26</td><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">90.74</td><td colspan="1" rowspan="1">53</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">113</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">81.42</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">34.38</td><td colspan="1" rowspan="1">103</td><td colspan="1" rowspan="1">91.15</td><td colspan="1" rowspan="1">58</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="3" rowspan="1"></td><td colspan="3" rowspan="1">Cazobactam: Enterobacter</td><td colspan="2" rowspan="1">les [Breakpoints</td><td colspan="1" rowspan="1">(ug/mL)</td><td colspan="1" rowspan="1">16(S). 32</td><td colspan="1" rowspan="1">-64 (I). 1</td><td colspan="1" rowspan="1">28 (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">815</td><td colspan="1" rowspan="1">728</td><td colspan="1" rowspan="1">89.33</td><td colspan="1" rowspan="1">641</td><td colspan="1" rowspan="1">554</td><td colspan="1" rowspan="1">86.43</td><td colspan="1" rowspan="1">768</td><td colspan="1" rowspan="1">94.23</td><td colspan="1" rowspan="1">56</td><td colspan="1" rowspan="1">730</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">107</td><td colspan="1" rowspan="1">96.4</td><td colspan="1" rowspan="1">36</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">88.89</td><td colspan="1" rowspan="1">110</td><td colspan="1" rowspan="1">99.1</td><td colspan="1" rowspan="1">92</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">926</td><td colspan="1" rowspan="1">835</td><td colspan="1" rowspan="1">90.17</td><td colspan="1" rowspan="1">677</td><td colspan="1" rowspan="1">586</td><td colspan="1" rowspan="1">86.56</td><td colspan="1" rowspan="1">878</td><td colspan="1" rowspan="1">94.82</td><td colspan="1" rowspan="1">148</td><td colspan="1" rowspan="1">749</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">4</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">aPiperac</td><td colspan="1" rowspan="1">llin-Tazc</td><td colspan="1" rowspan="1">bactam:</td><td colspan="1" rowspan="1">Pseudon</td><td colspan="1" rowspan="1">onas ael</td><td colspan="1" rowspan="1">uginosa</td><td colspan="1" rowspan="1">[Breakp</td><td colspan="1" rowspan="1">ints (ug</td><td colspan="1" rowspan="1">L); 16(</td><td colspan="1" rowspan="1">). 32-64</td><td colspan="1" rowspan="1">(I). 128</td><td colspan="1" rowspan="1">(R))</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">211</td><td colspan="1" rowspan="1">170</td><td colspan="1" rowspan="1">80.57</td><td colspan="1" rowspan="1">208</td><td colspan="1" rowspan="1">167</td><td colspan="1" rowspan="1">80.29</td><td colspan="1" rowspan="1">177</td><td colspan="1" rowspan="1">83.89</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">167</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">5fa$</td><td colspan="1" rowspan="1">83.33</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">80</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">83.33</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">217</td><td colspan="1" rowspan="1">175</td><td colspan="1" rowspan="1">80.65</td><td colspan="1" rowspan="1">213</td><td colspan="1" rowspan="1">171</td><td colspan="1" rowspan="1">80.28</td><td colspan="1" rowspan="1">182</td><td colspan="1" rowspan="1">83.87</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">167</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="7" rowspan="1">Tobramycin: Pseudomonas aeruginosa [Breakpoints (μg/mL): 4 (S), 8 (I), 16 (R)]</td><td colspan="1" rowspan="1">): 4 (S), 8</td><td colspan="1" rowspan="1">(I), 16 (</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">158</td><td colspan="1" rowspan="1">147</td><td colspan="1" rowspan="1">93.04</td><td colspan="1" rowspan="1">152</td><td colspan="1" rowspan="1">141</td><td colspan="1" rowspan="1">92.76</td><td colspan="1" rowspan="1">154</td><td colspan="1" rowspan="1">97.47</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">166</td><td colspan="1" rowspan="1">155</td><td colspan="1" rowspan="1">93.37</td><td colspan="1" rowspan="1">154</td><td colspan="1" rowspan="1">143</td><td colspan="1" rowspan="1">92.86</td><td colspan="1" rowspan="1">162</td><td colspan="1" rowspan="1">97.59</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">150</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">obactera</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">/mL</td><td colspan="1" rowspan="1">(S) - (I</td><td colspan="1" rowspan="1">4 (R)]</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Clinical</td><td colspan="1" rowspan="1">480</td><td colspan="1" rowspan="1">464</td><td colspan="1" rowspan="1">96.67</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">36</td><td colspan="1" rowspan="1">69.23</td><td colspan="1" rowspan="1">472</td><td colspan="1" rowspan="1">98.33</td><td colspan="1" rowspan="1">116</td><td colspan="1" rowspan="1">364</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">Challenge</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">43</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Combined</td><td colspan="1" rowspan="1">526</td><td colspan="1" rowspan="1">510</td><td colspan="1" rowspan="1">96.96</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">38</td><td colspan="1" rowspan="1">70.37</td><td colspan="1" rowspan="1">518</td><td colspan="1" rowspan="1">98.48</td><td colspan="1" rowspan="1">159</td><td colspan="1" rowspan="1">367</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">6</td></tr></table>

a Due to unacceptable performance, do not report Selux MIC results for these drug/organism combinations. EA – Essential Agreement R – Resistant isolates min – minor errors CA – Category Agreement NS – Non-susceptible isolates maj – major errors EVAL – Evaluable isolates S – Susceptible isolates vmj – very major errors

Table 7. Selux AST System – Gram-Negative Panel Trending   

<table><tr><td colspan="1" rowspan="1">Drug</td><td colspan="1" rowspan="1">Organism Name</td><td colspan="1" rowspan="1">Total OnScale forTrending</td><td colspan="1" rowspan="1">≥ 1 DilutionLower #(%)</td><td colspan="1" rowspan="1">Exact# (%)</td><td colspan="1" rowspan="1">≥ 1 DilutionHigher #(%)</td><td colspan="1" rowspan="1">PercentDifference(95% CI)</td><td colspan="1" rowspan="1">SignificantS TrendingNoteda</td></tr><tr><td colspan="1" rowspan="1">Amikacin</td><td colspan="1" rowspan="1">Pseudomonasaeruginosa</td><td colspan="1" rowspan="1">164</td><td colspan="1" rowspan="1">76(46.34)</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">10(6.1)</td><td colspan="1" rowspan="1">-40%(-48%, -31%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin-Clavulanate</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">179</td><td colspan="1" rowspan="1">64(35.75)</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">18(10.06)</td><td colspan="1" rowspan="1">-26%(-34%, -17%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin-Clavulanate</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">21(43.75)</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">9(18.75)</td><td colspan="1" rowspan="1">-25%(-41%, -6%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin-Clavulanate</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">142</td><td colspan="1" rowspan="1">89(62.68)</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">7(4.93)</td><td colspan="1" rowspan="1">-58%(-66%, -48%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin-Clavulanate</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">11(12.5)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">35(39.77)</td><td colspan="1" rowspan="1">27%(14%, 39%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">-74%</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Drug</td><td colspan="1" rowspan="1">Organism Name</td><td colspan="1" rowspan="1">Total OnScale for Trending</td><td colspan="1" rowspan="1">≥ 1 DilutionLower #(%)</td><td colspan="1" rowspan="1">Exact#(%)</td><td colspan="1" rowspan="1">≥ 1 DilutionHigher #(%)</td><td colspan="1" rowspan="1">PercentDifference(95% CI)</td><td colspan="1" rowspan="1">SignificantM TrendingNoteda</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">(76.19)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">(2.38)</td><td colspan="1" rowspan="1">(-82%, -62%)</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">81</td><td colspan="1" rowspan="1">25(30.86)</td><td colspan="1" rowspan="1">42</td><td colspan="1" rowspan="1">14(17.28)</td><td colspan="1" rowspan="1">-14%(-26%, 0%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ampicillin-su ubactam</td><td colspan="1" rowspan="1">Acinetobacterbaumanii (complex)</td><td colspan="1" rowspan="1">123</td><td colspan="1" rowspan="1">32(26.02)</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">31(25.2)</td><td colspan="1" rowspan="1">-1%(-12%, 10%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ampicillin-sulbactam</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">198</td><td colspan="1" rowspan="1">53(26.77)</td><td colspan="1" rowspan="1">118</td><td colspan="1" rowspan="1">27(13.64)</td><td colspan="1" rowspan="1">-13%(-21%, -5%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ampicillin-sulbactam</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">17(58.62)</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">4(13.79)</td><td colspan="1" rowspan="1">-45%(-63%, -20%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ampicillin-sulbactam</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">116</td><td colspan="1" rowspan="1">50(43.1)</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">31(26.72)</td><td colspan="1" rowspan="1">-16%(-28%, -4%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ampicillin-sulbactam</td><td colspan="1" rowspan="1">Morganella morganii</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">9(12)</td><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">19(25.33)</td><td colspan="1" rowspan="1">13%(1%, 26%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ampicillin-sulbactam</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">11(12.5)</td><td colspan="1" rowspan="1">58</td><td colspan="1" rowspan="1">19(21.59)</td><td colspan="1" rowspan="1">9%(-2%, 20%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ampicillin-sulbactam</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">2(3.23)</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">33(53.23)</td><td colspan="1" rowspan="1">50%(35%, 62%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Aztreonam</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">179</td><td colspan="1" rowspan="1">73(40.78)</td><td colspan="1" rowspan="1">81</td><td colspan="1" rowspan="1">25(13.97)</td><td colspan="1" rowspan="1">-27%(-35%, -18%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Cefazolin</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">171</td><td colspan="1" rowspan="1">81(47.37)</td><td colspan="1" rowspan="1">69</td><td colspan="1" rowspan="1">21(12.28)</td><td colspan="1" rowspan="1">-35%(-44%, -26%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefazolin</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">113</td><td colspan="1" rowspan="1">67(59.29)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">17(15.04)</td><td colspan="1" rowspan="1">-44%(-54%, -32%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Citrobacter freundii(complex)</td><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">11(14.29)</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">59(76.62)</td><td colspan="1" rowspan="1">62%(48%, 72%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">0()</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">72(100)</td><td colspan="1" rowspan="1">100%(93%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Enterobacter cloacae(complex)</td><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">13(16.88)</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">55(71.43)</td><td colspan="1" rowspan="1">55%(40%, 66%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">158</td><td colspan="1" rowspan="1">21(13.29)</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">129(81.65)</td><td colspan="1" rowspan="1">68%(59%, 75%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Klebsiella aerogenes</td><td colspan="1" rowspan="1">41</td><td colspan="1" rowspan="1">2(4.88)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">39(95.12)</td><td colspan="1" rowspan="1">90%(74%, 95%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">5(25</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">14(70)</td><td colspan="1" rowspan="1">45%(14%, 66%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">38(34.23)</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">60(54.05)</td><td colspan="1" rowspan="1">20%(7%, 32%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Morganella morganii</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">1(5.88)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">16(94.12)</td><td colspan="1" rowspan="1">88%(58%, 95%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">86</td><td colspan="1" rowspan="1">3(3.49)</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">81(94.19)</td><td colspan="1" rowspan="1">91%(81%, 95%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">90</td><td colspan="1" rowspan="1">4(4.44)</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">82(91.11)</td><td colspan="1" rowspan="1">87%(77%, 92%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">3(3.06)</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">93(94.9)</td><td colspan="1" rowspan="1">92%(83%, 95%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Cefoxitin</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">166</td><td colspan="1" rowspan="1">41(24.7)</td><td colspan="1" rowspan="1">87</td><td colspan="1" rowspan="1">38(22.89)</td><td colspan="1" rowspan="1">-2%(-11%, 7%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Cefoxitin</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">6(20.69)</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">7(24.14)</td><td colspan="1" rowspan="1">3%(-18%, 24%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Cefoxitin</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">109</td><td colspan="1" rowspan="1">27(24.77)</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">20(18.35)</td><td colspan="1" rowspan="1">-6%(-17%, 5%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Cefoxitin</td><td colspan="1" rowspan="1">Morganella morganii</td><td colspan="1" rowspan="1">59</td><td colspan="1" rowspan="1">10(16.95)</td><td colspan="1" rowspan="1">39</td><td colspan="1" rowspan="1">10(16.95)</td><td colspan="1" rowspan="1">0%(-14%, 14%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Drug</td><td colspan="1" rowspan="1">Organism Name</td><td colspan="1" rowspan="1">Total OnScale for Trending</td><td colspan="1" rowspan="1">≥ 1 DilutionLower #(%)</td><td colspan="1" rowspan="1">Exact#(%)</td><td colspan="1" rowspan="1">≥ 1 DilutionHigher #(%)</td><td colspan="1" rowspan="1">PercentDifference(95% CI)</td><td colspan="1" rowspan="1">SignificantS TrendingNoteda</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">Citrobacter freundii(complex)</td><td colspan="1" rowspan="1">53</td><td colspan="1" rowspan="1">12(22.64)</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">29(54.72)</td><td colspan="1" rowspan="1">32%(14%, 48%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">1(2.22)</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">42(93.33)</td><td colspan="1" rowspan="1">91%(77%, 96%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">Enterobacter cloacae(complex)</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">9(17.31)</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">33(63.46)</td><td colspan="1" rowspan="1">46%(28%, 60%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">74</td><td colspan="1" rowspan="1">31(41.89)</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">34(45.95)</td><td colspan="1" rowspan="1">4%(-12%, 20%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">Klebsiella aerogenes</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">2(6.9)</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">20(68.97)</td><td colspan="1" rowspan="1">62%(38%, 77%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">2(8.7)</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">18(78.26)</td><td colspan="1" rowspan="1">70%(42%, 83%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">73</td><td colspan="1" rowspan="1">12(16.44)</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">52(71.23)</td><td colspan="1" rowspan="1">55%(40%, 66%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">63</td><td colspan="1" rowspan="1">1(1.59)</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">58(92.06)</td><td colspan="1" rowspan="1">90%(79%, 95%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">2(4)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">47(94)</td><td colspan="1" rowspan="1">90%(76%, 95%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">56</td><td colspan="1" rowspan="1">3(5.36)</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">44(78.57)</td><td colspan="1" rowspan="1">73%(58%, 83%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Citrobacter freundii(complex)</td><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">11(18.03)</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">35(57.38)</td><td colspan="1" rowspan="1">39%(22%, 53%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">48(88.89)</td><td colspan="1" rowspan="1">89%(76%, 95%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Enterobacter cloacae(complex)</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">19(25.33)</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">29(38.67)</td><td colspan="1" rowspan="1">13%(-2%, 27%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">136</td><td colspan="1" rowspan="1">15(11.03)</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">101(74.26)</td><td colspan="1" rowspan="1">63%(53%, 71%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Klebsiella aerogenes</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">2(3.85)</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">39(75)</td><td colspan="1" rowspan="1">71%(55%, 81%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">3(10.71)</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">21(75)</td><td colspan="1" rowspan="1">64%(40%, 78%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">73</td><td colspan="1" rowspan="1">23(31.51)</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">31(42.47)</td><td colspan="1" rowspan="1">11%(-5%, 26%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Morganella morganii</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">1(1.61)</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">58(93.55)</td><td colspan="1" rowspan="1">92%(81%, 96%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">65</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">63(96.92)</td><td colspan="1" rowspan="1">97%(88%, 99%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">55</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">53(96.36)</td><td colspan="1" rowspan="1">96%(85%, 99%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Pseudomonasaeruginosa</td><td colspan="1" rowspan="1">158</td><td colspan="1" rowspan="1">70(44.3)</td><td colspan="1" rowspan="1">63</td><td colspan="1" rowspan="1">25(15.82)</td><td colspan="1" rowspan="1">-28%(-38%, -19%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-avibactam</td><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">66</td><td colspan="1" rowspan="1">10(15.15)</td><td colspan="1" rowspan="1">33</td><td colspan="1" rowspan="1">23(34.85)</td><td colspan="1" rowspan="1">20%(5%, 33%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">Citrobacter freundii(comlex)</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">8(16.33)</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">34(69.39)</td><td colspan="1" rowspan="1">53%(34%, 67%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">1(3.7)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">26(96.3)</td><td colspan="1" rowspan="1">93%(72%, 97%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">44</td><td colspan="1" rowspan="1">7(15.91)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">36(81.82)</td><td colspan="1" rowspan="1">66%(47%, 78%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">Klebsiella aerogenes</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">6(17.65)</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">25(73.53)</td><td colspan="1" rowspan="1">56%(33%, 71%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">5(17.24)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">23(79.31)</td><td colspan="1" rowspan="1">62%(37%, 77%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Drug</td><td colspan="1" rowspan="1">Organism Name</td><td colspan="1" rowspan="1">Total OnScale for Trending</td><td colspan="1" rowspan="1">≥ 1 DilutionLower #(%)</td><td colspan="1" rowspan="1">Exact#(%)</td><td colspan="1" rowspan="1">≥ 1 DilutionHigher ##(%</td><td colspan="1" rowspan="1">PercentDifference(95% CI)</td><td colspan="1" rowspan="1">SignificantS TrendingNoteda</td></tr><tr><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">107</td><td colspan="1" rowspan="1">52(48.6)</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">53(49.53)</td><td colspan="1" rowspan="1">1%(-12%, 14%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">5(13.51)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">32(86.49)</td><td colspan="1" rowspan="1">73%(53%, 84%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Citrobacter freundii(complex)</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">14(24.56)</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">36(63.16)</td><td colspan="1" rowspan="1">39%(21%, 53%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">36</td><td colspan="1" rowspan="1">1(2.78)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">34(94.44)</td><td colspan="1" rowspan="1">92%(75%, 96%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Enterobacter cloacae(complex)</td><td colspan="1" rowspan="1">68</td><td colspan="1" rowspan="1">14(20.59)</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">49(72.06)</td><td colspan="1" rowspan="1">51%(35%, 64%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">170</td><td colspan="1" rowspan="1">51(30)</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">102(60)</td><td colspan="1" rowspan="1">30%(20%, 40%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Klebsiella aerogenes</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">28(93.33)</td><td colspan="1" rowspan="1">93%(75%, 98%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">28</td><td colspan="1" rowspan="1">1(3.57)</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">21(775</td><td colspan="1" rowspan="1">71%(48%, 84%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">7(30.43)</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">11(47.83)</td><td colspan="1" rowspan="1">17%(-10%, 42%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Morganella morganii</td><td colspan="1" rowspan="1">58</td><td colspan="1" rowspan="1">3(5.17)</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">49(84.48)</td><td colspan="1" rowspan="1">79%(65%, 87%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">9(37.5)</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">10(41.67)</td><td colspan="1" rowspan="1">4%(-22%, 30%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">3(17.65)</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">11(64.71)</td><td colspan="1" rowspan="1">47%(14%, 68%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Pseudomonasaeruginosa</td><td colspan="1" rowspan="1">151</td><td colspan="1" rowspan="1">62(41.06)</td><td colspan="1" rowspan="1">74</td><td colspan="1" rowspan="1">15(9.93)</td><td colspan="1" rowspan="1">-31%(-40%, -22%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Eravacycline</td><td colspan="1" rowspan="1">Citrobacter freundii(complex)</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">2(3.23)</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">28(45.16)</td><td colspan="1" rowspan="1">42%(28%, 54%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Eravacycline</td><td colspan="1" rowspan="1">Enterobacter cloacae(complex)</td><td colspan="1" rowspan="1">76</td><td colspan="1" rowspan="1">13(17.11)</td><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">16(21.05)</td><td colspan="1" rowspan="1">4%(-9%, 16%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Eravacycline</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">167</td><td colspan="1" rowspan="1">40(23.95)</td><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">28(16.77)</td><td colspan="1" rowspan="1">-7%(-16%, 1%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Eravacycline</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">4(8.51)</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">13(27.66)</td><td colspan="1" rowspan="1">19%(3%, 34%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">Citrobacter freundii(complex)</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">3(12.5)</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">16(66.67)</td><td colspan="1" rowspan="1">54%(27%, 72%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">0()</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">72(100)</td><td colspan="1" rowspan="1">100%(93%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">210</td><td colspan="1" rowspan="1">11(5.24)</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">188(89.52)</td><td colspan="1" rowspan="1">84%(78%, 88%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">1(33.33)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">1(33.33)</td><td colspan="1" rowspan="1">0%(-53%, 53%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">10(43.48)</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">7(30.43)</td><td colspan="1" rowspan="1">-13%(-38%, 14%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">Morganella morganii</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">7(70)</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">1(10)</td><td colspan="1" rowspan="1">-60%(-81%, -17%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">85</td><td colspan="1" rowspan="1">2(2.35)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">83(97.65)</td><td colspan="1" rowspan="1">95%(87%, 98%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">97(98.98)</td><td colspan="1" rowspan="1">99%(93%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">65</td><td colspan="1" rowspan="1">6(9.23)</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">48(73.85)</td><td colspan="1" rowspan="1">65%(49%, 75%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Citrobacter freundii(complex)</td><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">41(64.06)</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">1(1.56)</td><td colspan="1" rowspan="1">-62%(-73%, -49%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Drug</td><td colspan="1" rowspan="1">Organism Name</td><td colspan="1" rowspan="1">Total OnSScale forTrending</td><td colspan="1" rowspan="1">≥ 1 DilutionLower #(%)</td><td colspan="1" rowspan="1">Exact#(%)</td><td colspan="1" rowspan="1">≥ 1 DilutionHigher #(%)</td><td colspan="1" rowspan="1">PercentDifference(95% CI)</td><td colspan="1" rowspan="1">Significant TrendingNoteda</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">23(42.59)</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">8(14.81)</td><td colspan="1" rowspan="1">-28%(-43%, -11%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Enterobacter cloacae(complex)</td><td colspan="1" rowspan="1">74</td><td colspan="1" rowspan="1">36(48.65)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">7(9.46)</td><td colspan="1" rowspan="1">-39%(-51%, -25%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">173</td><td colspan="1" rowspan="1">84(48.55)</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">11(6.36)</td><td colspan="1" rowspan="1">-42%(-50%, -34%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Klebsiella aerogenes</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">8(25.81)</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">5(16.13)</td><td colspan="1" rowspan="1">-10%(-29%, 11%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">14(48.28)</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">0()</td><td colspan="1" rowspan="1">-48%(-66%, -28%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">126</td><td colspan="1" rowspan="1">58(46.03)</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">6(4.76)</td><td colspan="1" rowspan="1">-41%(-50%, -31%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">12(18.75)</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">23(35.94)</td><td colspan="1" rowspan="1">17%(2%, 32%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">55</td><td colspan="1" rowspan="1">13(23.64)</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">15(27.27)</td><td colspan="1" rowspan="1">4%(-13%, 20%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Pseudomonasaeruginosa</td><td colspan="1" rowspan="1">211</td><td colspan="1" rowspan="1">68(32.23)</td><td colspan="1" rowspan="1">79</td><td colspan="1" rowspan="1">64(30.33)</td><td colspan="1" rowspan="1">-2%(-11%, 7%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">68</td><td colspan="1" rowspan="1">3(4.41)</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">42(61.76)</td><td colspan="1" rowspan="1">57%(43%, 68%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Imipenem-Relebactam</td><td colspan="1" rowspan="1">Citrobacter freundii(complex)</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">28(51.85)</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">7(12.96)</td><td colspan="1" rowspan="1">-39%(-53%,-22%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Imipenem-Relebactam</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">55</td><td colspan="1" rowspan="1">18(32.73)</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">13(23.64)</td><td colspan="1" rowspan="1">-9%(-25%, 8%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Imipenem-Relebactam</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">172</td><td colspan="1" rowspan="1">40(23.26)</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">31(18.02)</td><td colspan="1" rowspan="1">-5%(-14%, 3%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Imipenem-Relebactam</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">8(29.63)</td><td colspan="1" rowspan="1">30%(11%, 48%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Imipenem-Relebactam</td><td colspan="1" rowspan="1">Pseudomonasaeruginosa</td><td colspan="1" rowspan="1">162</td><td colspan="1" rowspan="1">22(13.58)</td><td colspan="1" rowspan="1">119</td><td colspan="1" rowspan="1">21(12.96)</td><td colspan="1" rowspan="1">-1%(-8%,7%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Citrobacter freundii(complex)</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">6(10)</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">42(70)</td><td colspan="1" rowspan="1">60%(44%, 71%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">54(100)</td><td colspan="1" rowspan="1">100%(91%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Enterobacter cloacae(complex)</td><td colspan="1" rowspan="1">68</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">63(92.65)</td><td colspan="1" rowspan="1">93%(82%, 97%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">169</td><td colspan="1" rowspan="1">13(7.69)</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">125(73.96)</td><td colspan="1" rowspan="1">66%(58%, 73%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Klebsiella aerogenes</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">1(3.12)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">30(93.75)</td><td colspan="1" rowspan="1">91%(72%, 96%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">1(3.7)</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">22(81.48)</td><td colspan="1" rowspan="1">78%(54%, 89%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">84</td><td colspan="1" rowspan="1">9(10.71)</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">62(73.81)</td><td colspan="1" rowspan="1">63%(50%, 73%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Morganella morganii</td><td colspan="1" rowspan="1">61</td><td colspan="1" rowspan="1">4(6.56)</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">54(88.52)</td><td colspan="1" rowspan="1">82%(68%, 89%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">65</td><td colspan="1" rowspan="1">3(4.62)</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">53(81.54)</td><td colspan="1" rowspan="1">77%(63%, 85%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">55</td><td colspan="1" rowspan="1">1(1.82)</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">48(87.27)</td><td colspan="1" rowspan="1">85%(72%, 92%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">68</td><td colspan="1" rowspan="1">15(22.06)</td><td colspan="1" rowspan="1">34</td><td colspan="1" rowspan="1">19(27.94)</td><td colspan="1" rowspan="1">6%(-9%, 20%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Citrobacter freundii(complex)</td><td colspan="1" rowspan="1">78</td><td colspan="1" rowspan="1">2(2.56)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">75(96.15)</td><td colspan="1" rowspan="1">94%(84%, 97%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Drug</td><td colspan="1" rowspan="1">Organism Name</td><td colspan="1" rowspan="1">Total OnScale for Trending</td><td colspan="1" rowspan="1">≥ 1 Dilutionower #(%)</td><td colspan="1" rowspan="1">Exact#(%</td><td colspan="1" rowspan="1">≥ 1 DilutionHigher #(%)</td><td colspan="1" rowspan="1">PercentDifference(95% CI)</td><td colspan="1" rowspan="1">SignificantS TrendingNoteda</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">0()</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">71(98.61)</td><td colspan="1" rowspan="1">99%(91%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Enterobacter cloacae(complex)</td><td colspan="1" rowspan="1">74</td><td colspan="1" rowspan="1">5(6.76)</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">63(85.14)</td><td colspan="1" rowspan="1">78%(66%, 86%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">2(40)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">3(60)</td><td colspan="1" rowspan="1">20%(-32%, 60%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">27(100)</td><td colspan="1" rowspan="1">100%(82%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">106</td><td colspan="1" rowspan="1">14(13.21)</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">77(72.64)</td><td colspan="1" rowspan="1">59%(47%, 69%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Morganella morganii</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">1(1.61)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">60(96.77)</td><td colspan="1" rowspan="1">95%(85%, 98%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">66</td><td colspan="1" rowspan="1">1(1.52)</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">62(93.94)</td><td colspan="1" rowspan="1">92%(82%, 96%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">0()</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">51(100)</td><td colspan="1" rowspan="1">100%(90%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Pseudomonasaeruginosa</td><td colspan="1" rowspan="1">167</td><td colspan="1" rowspan="1">52(31.14)</td><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">38(22.75)</td><td colspan="1" rowspan="1">-8%(-18%, 1%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">3(2.94)</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">97(95.1)</td><td colspan="1" rowspan="1">92%(84%, 96%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem-vaborbactam</td><td colspan="1" rowspan="1">Citrobacter freundii(complex)</td><td colspan="1" rowspan="1">57</td><td colspan="1" rowspan="1">0()</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">56(98.25)</td><td colspan="1" rowspan="1">98%(88%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem-vaborbactam</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">48(100)</td><td colspan="1" rowspan="1">100%(90%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem-vaborbactam</td><td colspan="1" rowspan="1">Enterobacter cloacae(complex)</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">51(98.08)</td><td colspan="1" rowspan="1">98%(87%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem-vaborbactam</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">4(13.79)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">25(86.21)</td><td colspan="1" rowspan="1">72%(49%, 84%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem-vaborbactam</td><td colspan="1" rowspan="1">Klebsiella aerogenes</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">0()</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">49(98)</td><td colspan="1" rowspan="1">98%(87%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem-vaborbactam</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">47</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">47(100)</td><td colspan="1" rowspan="1">100%(89%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem-vaborbactam</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">4(4)</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">90(90)</td><td colspan="1" rowspan="1">86%(77%, 91%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem-vaborbactam</td><td colspan="1" rowspan="1">Morganella morganii</td><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">0()</td><td colspan="1" rowspan="1">35</td><td colspan="1" rowspan="1">29(45.31)</td><td colspan="1" rowspan="1">45%(32%, 57%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Meropenem-vaborbactam</td><td colspan="1" rowspan="1">Serratia marcescens</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">59(98.33)</td><td colspan="1" rowspan="1">98%(89%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Minocycline</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">198</td><td colspan="1" rowspan="1">43(21.72)</td><td colspan="1" rowspan="1">83</td><td colspan="1" rowspan="1">72(36.36)</td><td colspan="1" rowspan="1">15%(6%, 23%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Minocycline</td><td colspan="1" rowspan="1">Klebsiella aerogenes</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">17(32.69)</td><td colspan="1" rowspan="1">30</td><td colspan="1" rowspan="1">5(9.62)</td><td colspan="1" rowspan="1">-23%(-38%, -7%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Minocycline</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">3(11.11)</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">9(33.33)</td><td colspan="1" rowspan="1">22%(0%, 42%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Minocycline</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">126</td><td colspan="1" rowspan="1">38(30.16)</td><td colspan="1" rowspan="1">66</td><td colspan="1" rowspan="1">22(17.46)</td><td colspan="1" rowspan="1">-13%(-23% -2%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Piperacillin-tazobactam</td><td colspan="1" rowspan="1">Citrobacter koseri</td><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">15(20)</td><td colspan="1" rowspan="1">49</td><td colspan="1" rowspan="1">11(14.67)</td><td colspan="1" rowspan="1">-5%(-17%, 7%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Piperacillin-tazobactam</td><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">175</td><td colspan="1" rowspan="1">47(26.86)</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">37(21.14)</td><td colspan="1" rowspan="1">-6%(-15%, 3%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Piperacillin-tazobactam</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">11(40.74)</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">1(3.7)</td><td colspan="1" rowspan="1">-37%(-56%, -15%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Piperacillin-tazobactam</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">132</td><td colspan="1" rowspan="1">80(60.61)</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">15(11.36)</td><td colspan="1" rowspan="1">-49%(-58%, -38%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Drug</td><td colspan="1" rowspan="1">Organism Name</td><td colspan="1" rowspan="1">Total OnScale forTrending</td><td colspan="1" rowspan="1">≥ 1 DilutionLower #(%)</td><td colspan="1" rowspan="1">Exact# (%)</td><td colspan="1" rowspan="1">≥ 1 DilutionHigher #(%)</td><td colspan="1" rowspan="1">PercentDifference(95% CI)</td><td colspan="1" rowspan="1">SignificantS TrendingNoteda</td></tr><tr><td colspan="1" rowspan="1">Piperacillin-tazobactam</td><td colspan="1" rowspan="1">Morganella morganii</td><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">12(18.75)</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">36(56.25)</td><td colspan="1" rowspan="1">38%(21%, 51%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Piperacillin-tazobactam</td><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">70</td><td colspan="1" rowspan="1">15(21.43)</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">43(61.43)</td><td colspan="1" rowspan="1">40%(24%, 53%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Piperacillin-tazobactam</td><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">34(68)</td><td colspan="1" rowspan="1">68%(52%, 79%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Tobramycin</td><td colspan="1" rowspan="1">Pseudomonasaeruginosa</td><td colspan="1" rowspan="1">162</td><td colspan="1" rowspan="1">25(15.43)</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">46(28.4)</td><td colspan="1" rowspan="1">13%(4%, 22%)</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">TrimethoprimSulfamethoxazole</td><td colspan="1" rowspan="1">Enterobacter cloacae(complex)</td><td colspan="1" rowspan="1">72</td><td colspan="1" rowspan="1">17(23.61)</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">44(61.11)</td><td colspan="1" rowspan="1">38%(22%, 51%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">TrimethoprimSulfamethoxazole</td><td colspan="1" rowspan="1">Klebsiella aerogenes</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">2(6.25)</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">29(90.62)</td><td colspan="1" rowspan="1">84%(64%, 92%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">TrimethoprimSulfamethoxazole</td><td colspan="1" rowspan="1">Klebsiella oxytoca</td><td colspan="1" rowspan="1">22</td><td colspan="1" rowspan="1">0(0)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">22(100)</td><td colspan="1" rowspan="1">100%(79%, 100%)</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">TrimethoprimSulfamethoxazole</td><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">66</td><td colspan="1" rowspan="1">6(9.09)</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">55(83.33)</td><td colspan="1" rowspan="1">74%(60%, 83%)</td><td colspan="1" rowspan="1">Yes</td></tr></table>

a Significant trending as determined by a statistically significant confidence interval.

Characterized Resistance Mechanisms. The molecular characteristics of the challenge isolates evaluated in the clinical study, provided by the FDA-CDC AR Isolate Bank, are provided in Table 8.

Table 8. M olecular characteristics of resistance markers in cha llenge isolates.   

<table><tr><td rowspan=1 colspan=1>Antimicrobial</td><td rowspan=1 colspan=1>Drug-Class Specific</td><td rowspan=1 colspan=1>Truncated Porins</td></tr><tr><td rowspan=1 colspan=1>Amikacin</td><td rowspan=1 colspan=1>3)-Ila,ac(3-Idc(6&#x27;-IA, nt(2&quot;)-la,h(3-Ich(3-Vla,A srA, trBac3-a</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Amoxicillin-Clavulanate</td><td rowspan=1 colspan=1>CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, KPC-2, KPC-3, NDM-1, NDM-5, NDM-7, OXA-1,OXA-10, OXA-181, OXA-2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26, SHV-28, SHV-30, SHV-83, TEM-1A, TEM-1B, VIM-1, VIM-27</td><td rowspan=1 colspan=1>OmpC2, OmpK35, OmpK36, OmpF</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>CMY-42, CTX-M-15, KPC-3, NDM-5, OXA-1, OXA-9, SHV-12, TEM-1A, TEM-1B</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Ampicillin-Sulbactam</td><td rowspan=1 colspan=1>CMY-4, CMY-6, CMY-42, CTX-M-2, CTX-M-15, KPC-3, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-2, OXA-23, OXA-232, OXA-69, OXA-9, SHV-11, SHV-12, SHV-83, TEM-1A, TEM-1B, TEM-1D, VIM-27</td><td rowspan=1 colspan=1>OmpF, OmpK35, OmpK36</td></tr><tr><td rowspan=1 colspan=1>Aztreonam</td><td rowspan=1 colspan=1>carB-2, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, KPC-2, KPC-3, NDM-1, NDM-5, OXA-1, OXA-2,OXA-10, OXA-50, OXA-9, SHV-12, TEM-1A, TEM-1B, VEB-1, VEB-5</td><td rowspan=1 colspan=1>OmpF</td></tr><tr><td rowspan=1 colspan=1>Cefazolin</td><td rowspan=1 colspan=1>CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, KPC-2, NDM-1, OXA-1, OXA-10, OXA-181, OXA-232, OXA-9, SHV-1, SHV-11, SHV-12, SHV-154, SHV-26, SHV-83, TEM-1A, TEM-1B, VEB-5</td><td rowspan=1 colspan=1>OmpF, OmpK35, OmpK36</td></tr><tr><td rowspan=1 colspan=1>Cefepime</td><td rowspan=1 colspan=1>ACT-7, ACT-16, carB-2, CMY-42, CMY-6, CTX-M-15, CTX-M-2, IMP-1, KPC-2, KPC-6, NDM-1, OXA-1,OXA-10, OXA-181, OXA-2, OXA-232, OXA-50, OXA-9, PAO, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26,SHV-28, SHV-83, TEM-1A, TEM-1B, VEB-1, VEB-5, VIM-1</td><td rowspan=1 colspan=1>OmpC2, OmpK35, OmpK36, OmpF</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, KPC-2, NDM-1, NDM-7, OXA-1, OXA-10, OXA-181, OXA2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV-12, SHV-28, SHV-83, TEM-1A, TEM-1B</td><td rowspan=1 colspan=1>OmpC2, OmpK35, OmpK36, OmpF</td></tr><tr><td rowspan=1 colspan=1>Ceftazidime</td><td rowspan=1 colspan=1>ACT-7, ACT-16, ADC-25, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, IMP-1, IMP-8, KPC-2,KPC-3, KPC-6, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-2, OXA-23, OXA-232, OXA-24,OXA-50, OXA-65, OXA-66, OXA-69, OXA-71, OXA-9, OXA-94, PAO, SHV-1, SHV-100, SHV-11, SHV-12,SHV-26, SHV-28, SHV-30, SHV-5, SHV-83, SME-3, TEM-1A, TEM-1B, TEM-1D, VEB-1, VEB-5, VIM-1,VIM-2, VIM-27</td><td rowspan=1 colspan=1>OmpC2, OmpF, OmpK35, OmpK36</td></tr><tr><td rowspan=1 colspan=1>Ceftazidime-Avibactam</td><td rowspan=1 colspan=1>ACT-7, CMY-4, CMY-42, CMY-6, CTX-M-15, IMP-1, IMP-8, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10,OXA-101, OXA-181, OXA-2, OXA-232, OXA-50, OXA-9, PAO, SHV-100, SHV-11, SHV-12, SHV-26, SHV-28, SHV-30, SME-3, TEM-1A, TEM-1B, VEB-1, VIM-1, VIM-2, VIM-2</td><td rowspan=1 colspan=1>OmpC2, OmpF, OmpK35</td></tr><tr><td rowspan=1 colspan=1>Ceftriaxone</td><td rowspan=1 colspan=1>ACT-7, CMY-2, CMY-4, CMY-42, CTX-M-15, CTX-M-2, KPC-2, NDM-1, NDM-7, OXA-1, OXA-10, OXA-181, OXA-232, OXA-9, SHV-100, SHV-11, SHV-12, SHV-26, SHV-28, SHV-83, SME-3, TEM-1A, TEM-1B,VEB-5, VIM-27</td><td rowspan=1 colspan=1>OmpC2, OmpK35, OmpK36, OmpF</td></tr><tr><td rowspan=1 colspan=1>Ciprofloxacin</td><td rowspan=1 colspan=1>QnrB1, QnrB7, QnrS1, oqxA, oqxB,QnrB34</td><td rowspan=1 colspan=1>OmpC2, OmpK35, OmpK36, OmpF</td></tr><tr><td rowspan=1 colspan=1>Eravacycline</td><td rowspan=1 colspan=1>tet(A), tet(D), tet(G), tet(R)</td><td rowspan=1 colspan=1>OmpC2, OmpK35</td></tr><tr><td rowspan=1 colspan=1>Ertapenem</td><td rowspan=1 colspan=1>ACT-16, ACT-7, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, CTX-M-2, IMP-8, KPC-2, KPC-6, NDM-1,NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV-12, SHV-154, SHV-26, SHV-28, SHV-83, SME-3, TEM-1A, TEM-1B, VEB-5, VIM-27</td><td rowspan=1 colspan=1>OmpC2, OmpK35, OmpK36, OmpF</td></tr><tr><td rowspan=1 colspan=1>Gentamicin</td><td rowspan=1 colspan=1>(3)-Ila,ac(3)-I,ac(3)-Iaac(6-Ila, c(6&#x27;-Ic,ac(6-anac(6&#x27;-Ib-c,ac(6&#x27;-A1,An(2ah3ah(3-Ih(3Vh(3Vh(IrmtB, rmtC, rmtG, strA, strB,aac(6&#x27;)-Ib</td><td rowspan=1 colspan=1>OmpC2, OmpK35, OmpK36, OmpF</td></tr><tr><td rowspan=1 colspan=1>Imipenem</td><td rowspan=1 colspan=1>ADC-25, OXA-23, OXA-24, OXA-65, OXA-66, OXA-69, OXA-71, SHV-5, TEM-1D</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Imipenem-Relebactam</td><td rowspan=1 colspan=1>BCR1, CMY-4, CMY-42, CMY-6, CTX-M-15, IMP-1, KPC-2, KPC-3, NDM-1, NDM-5, NDM-7, OXA-1,OXA-10, OXA-181, OXA-2, OXA-232, OXA-50, OXA-9, PAO, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26,SHV-28, SHV-30, TEM-1A, TEM-1B, VIM-1, VIM-2, VIM-27</td><td rowspan=1 colspan=1>OmpC2, OmpK35, OmpK36, OmpF</td></tr><tr><td rowspan=1 colspan=1>Levofloxacin</td><td rowspan=1 colspan=1>QnrB1, QnrB34, QnrB7, QnrS1, oqxA, oqxB,norA</td><td rowspan=1 colspan=1>OmpC2, OmpF, OmpK35, OmpK36</td></tr><tr><td rowspan=1 colspan=1>Meropenem</td><td rowspan=1 colspan=1>ACT-7, ADC-25, BCR1, carB-2, CMY-4, CMY-42, CMY-6, CTX-M-15, IMP-1, KPC-2, NDM-1, NDM-5,NDM-7, OXA-1, OXA-10, OXA-101, OXA-181, OXA-2, OXA-23, OXA-232, OXA-24, OXA-50, OXA-65,OXA-66, OXA-69, OXA-71, OXA-9, OXA-94, PAO, SHV-1, SHV-100, SHV-11, SHV-12, SHV-28, SHV-5,SME-3, TEM-1A, TEM-1B, TEM-1D, VEB-1, VIM-2, VIM-27</td><td rowspan=1 colspan=1>OmpC2, OmpF, OmpK35</td></tr><tr><td rowspan=1 colspan=1>Meropenem-Vaborbactam</td><td rowspan=1 colspan=1>CMY-4, CMY-42, CMY-6, CTX-M-15, KPC-2, NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-2, OXA-232, OXA-9, SHV-1, SHV-100, SHV-11, SHV-12, SHV-28, TEM-1A, TEM-1B, VIM-27</td><td rowspan=1 colspan=1>OmpC2, OmpK35, OmpK36, OmpF</td></tr><tr><td rowspan=1 colspan=1>Minocycline</td><td rowspan=1 colspan=1>tet(A), tet(A), tet(D), tet(K), tet(R),tet(38)</td><td rowspan=1 colspan=1>OmpK35</td></tr><tr><td rowspan=1 colspan=1>Piperacillin-Tazobactam</td><td rowspan=1 colspan=1>ACT-7, ACT-16, ADC-25, carB-2, CMY-2, CMY-4, CMY-42, CMY-6, CTX-M-15, KPC-2, KPC-3, KPC-6,NDM-1, NDM-5, NDM-7, OXA-1, OXA-10, OXA-181, OXA-2, OXA-23, OXA-232, OXA-24, OXA-50, OXA-65, OXA-69, OXA-71, OXA-9, OXA-94, SHV-1, SHV-100, SHV-11, SHV-12, SHV-26, SHV-28, SHV-5, TEM-1A, TEM-1B, TEM-1D, VIM-27</td><td rowspan=1 colspan=1>OmpC2, OmpF, OmpK35</td></tr><tr><td rowspan=1 colspan=1>Tobramycin</td><td rowspan=1 colspan=1>aac(6&#x27;)-Il, aadA1, aadA6, aadB, ant(2&quot;)-la, strA, strB,aac(3)-Id</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Trimethoprim-Sulfamethoxazole</td><td rowspan=1 colspan=1>dfrA1, dfrA12, dfrA14, dfrA15, dfrA17, dfrA29, dfrB5</td><td rowspan=1 colspan=1>OmpC2, OmpK35, OmpK36, OmpF</td></tr></table>

Non-indicated species. As required under 511A(b)(2)(C)(ii)(I) of the Federal Food, Drug and Cosmetic Act, the following statement is included in the Precautions section of the device labeling to address testing and reporting of non-indicated species:

Per the FDA-Recognized Susceptibility Test Interpretive Criteria Website, the safety and efficacy of antimicrobial drugs, for which antimicrobial susceptibility is tested by this AST device, may or may not have been established in adequate and well-controlled clinical trials for treating infections due to microorganisms outside of those found in the indications and usage in the drug label. The clinical significance of susceptibility information in those instances is unknown. The approved labeling for specific antimicrobial drugs provides the uses for which the antimicrobial drug is approved.

2. Matrix Comparison: Not applicable.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable.

D Clinical Cut-Off: Not applicable.

# E Expected Values/Reference Range:

The FDA-recognized/approved susceptibility test interpretive criteria (breakpoints) for the antimicrobials evaluated with the Selux AST System are listed in the table below.

Table 9. FDA-Approved or Recognized Interpretive Criteria1   

<table><tr><td colspan="1" rowspan="2">Antimicrobial</td><td colspan="1" rowspan="2">Organism</td><td colspan="3" rowspan="1">Minimum InhibitoryConcentration (μg/mL)</td></tr><tr><td colspan="1" rowspan="1">S</td><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">R</td></tr><tr><td colspan="1" rowspan="1">Amikacin</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">≤16</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">≥64</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin-Clavulanate</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤8</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">≥32</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤8</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">≥32</td></tr><tr><td colspan="1" rowspan="1">Ampicillin-sulbactam</td><td colspan="1" rowspan="1">Acinetobacter spp.,Enterobacterales</td><td colspan="1" rowspan="1">≤8</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">≥32</td></tr><tr><td colspan="1" rowspan="1">Aztreonam</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤4</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">≥16</td></tr><tr><td colspan="1" rowspan="1">Cefazolin</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤1</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">≥4</td></tr><tr><td colspan="1" rowspan="1">Cefepime</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤2</td><td colspan="1" rowspan="1">4-8</td><td colspan="1" rowspan="1">≥16</td></tr><tr><td colspan="1" rowspan="1">Cefoxitin</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤4</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">≥16</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤4</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">≥16</td></tr><tr><td colspan="1" rowspan="1">Ceftazidime-Avibactam</td><td colspan="1" rowspan="1">Enterobacterales,Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">≤8</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">≥16</td></tr><tr><td colspan="1" rowspan="1">Ceftriaxone</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤1</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">≥4</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤0.25</td><td colspan="1" rowspan="1">0.5</td><td colspan="1" rowspan="1">≥1</td></tr><tr><td colspan="1" rowspan="1">Ciprofloxacin</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">≤0.5</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">≥2</td></tr><tr><td colspan="1" rowspan="1">Eravacycline</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤0.5</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Ertapenem</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤0.5</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">≥2</td></tr><tr><td colspan="1" rowspan="1">Gentamicin</td><td colspan="1" rowspan="1">Enterobacterales,Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">≤4</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">≥16</td></tr><tr><td colspan="1" rowspan="1">Imipenem-Relebactam</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤1</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">≥4</td></tr><tr><td colspan="1" rowspan="1">Imipenem-Relebactam</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">≤2</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">≥8</td></tr><tr><td colspan="1" rowspan="1">Levofloxacin</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤0.5</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">≥2</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤1</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">≥4</td></tr><tr><td colspan="1" rowspan="1">Meropenem</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">≤2</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">≥8</td></tr><tr><td colspan="1" rowspan="1">Meropenem-Vaborbactam</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤4</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">≥16</td></tr><tr><td colspan="1" rowspan="1">Minocycline</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤4</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">≥16</td></tr><tr><td colspan="1" rowspan="1">Piperacillin-tazobactam</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">≤16</td><td colspan="1" rowspan="1">32-64</td><td colspan="1" rowspan="1">≥128</td></tr><tr><td colspan="1" rowspan="1">Tobramycin</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">≤4</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">≥16</td></tr><tr><td colspan="1" rowspan="1">Trimethoprim-Sulfamethoxazole</td><td colspan="1" rowspan="1">Enterobacterales</td><td colspan="1" rowspan="1">≤2</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">≥4</td></tr></table>

${ \mathbf { S } } =$ Susceptible; $\mathrm { I } =$ Intermediate; $\mathrm { R } =$ Resistant; $\mathbf { \Pi } _ { - } = \mathbf { n } 0$ interpretive criterion recognized 1 According to the FDA-Recognized Antimicrobial Susceptibility Test Interpretive Criteria Website https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm4 10971.htm

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

To support the implementation of changes to FDA-recognized susceptibility test interpretive criteria (i.e., breakpoints), this submission included a breakpoint change protocol that was reviewed and accepted by FDA. This protocol addresses future revisions to device labeling in response to breakpoint changes that are recognized on the FDA STIC webpage (https://www.fda.gov/drugs/development-resources/fda-recognized-antimicrobial-susceptibilitytest-interpretive-criteria). The protocol outlined the specific procedures and acceptance criteria that Selux intends to use to evaluate the Selux AST System when revised breakpoints for the following antimicrobials are published on the FDA STIC webpage: Amikacin, AmoxicillinClavulanate, Ampicillin, Ampicillin-sulbactam, Aztreonam, Cefazolin, Cefepime, Cefoxitin, Ceftazidime, Ceftazidime-Avibactam, Ceftriaxone, Ciprofloxacin, Eravacycline, Ertapenem, Gentamicin, Imipenem-Relebactam, Levofloxacin, Meropenem, Meropenem-Vaborbactam, Minocycline, Piperacillin-Tazobactam, Tobramycin, Trimethoprim-Sulfamethoxazole.

The breakpoint change protocol included with the submission indicated that if specific criteria are met, Selux will update the device label to include (1) the new breakpoints, (2) an updated performance section after re-evaluation of data in this premarket notification with the new breakpoints, and (3) any new limitations as determined by their evaluation.